[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 70 of about 70
1. Umeda M, Murata M, Suzuki H, Yanagida T, Shibuya Y, Komori T: A case of malignant melanoma of the oral cavity alive with liver metastasis for a long period with administration of a biologic response modifier, OK432. Kobe J Med Sci; 2010;56(3):E140-7
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of malignant melanoma of the oral cavity alive with liver metastasis for a long period with administration of a biologic response modifier, OK432.
  • A patient with malignant melanoma of the oral cavity who lived for a long period despite developing liver metastasis is presented.
  • An 81-year-old female was referred to our hospital because of a pigmented tumor of the lower gingiva.
  • Under the clinical diagnosis of malignant melanoma, she underwent bilateral functional neck dissection and marginal mandiblectomy.
  • Histological diagnosis of the operation material was malignant melanoma with regional lymph node metastasis.
  • In spite of loco-regional control, liver metastasis developed at 7 months after the surgery.
  • She then underwent combination chemotherapies with dimethyl triazeno imidazole carboxamide (DTIC), nimustine hydrochloride (ACNU) and vincristin (DAV therapy), or cisplatin, DTIC, ACNU and tamoxifen (DAC-tam), but no marked response was obtained.
  • Considering the advanced age of the patient, immunotherapy with a biological response modifier, OK432, alone was started.
  • After administration of OK432, the metastatic tumor gradually decreased, and she is alive without any clinical symptoms of tumor at 46 months after the detection of liver metastasis, although it is still present on ultrasonic and CT examinations.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Liver Neoplasms / drug therapy. Melanoma / drug therapy. Mouth Neoplasms / drug therapy. Picibanil / administration & dosage
  • [MeSH-minor] Aged, 80 and over. Female. Humans. Lymphatic Metastasis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21063154.001).
  • [ISSN] 1883-0498
  • [Journal-full-title] The Kobe journal of medical sciences
  • [ISO-abbreviation] Kobe J Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 39325-01-4 / Picibanil
  •  go-up   go-down


2. Lo RH, Chang KP, Chu ST: Malignant mucosal melanoma in the nasal cavity: an uncommon cause of epistaxis. J Chin Med Assoc; 2010 Sep;73(9):496-8
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mucosal melanoma in the nasal cavity: an uncommon cause of epistaxis.
  • Malignant mucosal melanoma of the nasal cavity is extremely rare.
  • It is usually diagnosed in the elderly.
  • Physical examination showed a dark-colored mass lesion over the left nasal cavity, and biopsy of it revealed malignant melanoma.
  • Wide excision of the tumor was performed via endoscopic surgery, and adjuvant radiotherapy was also arranged.
  • Diagnosis of malignant melanoma mainly depends on histochemistry and immunostain.
  • Up to now, surgery offers the best chance for local tumor control.
  • However, postoperative radiotherapy or chemotherapy is often needed because mucosal melanomas tend to have distant metastasis and local failure.
  • [MeSH-major] Epistaxis / etiology. Melanoma / pathology. Nasal Cavity. Nose Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20875625.001).
  • [ISSN] 1728-7731
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


3. Stadler P, Putnik K, Kreimeyer T, Sprague LD, Koelbl O, Schäfer C: Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis. BMC Cancer; 2006;6:279
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis.
  • BACKGROUND: The advantage of hyperfractionated accelerated radiation therapy for advanced head and neck cancer has been reported.
  • Furthermore, randomized trials and meta-analyses have confirmed the survival benefit of additional chemotherapy to radiotherapy.
  • We retrospectively analyzed the efficiency and toxicity of the Regensburg standard therapy protocol "SCHARC" and the overall survival of our patients.
  • METHODS: From 1997 to 2004, 64 patients suffering from advanced head and neck cancer (88 % stage IV, 12 % stage III) were assigned to receive the SCHARC protocol.
  • Around half of the patients were diagnosed with oro-hypopharynx carcinoma (52 %), one third with tongue and floor of mouth tumors (29 %) and one fifth (19 %) suffered from H & N cancer at other sites.
  • The schedule consisted of one therapy block with 30 Gy in 20 fractions over a two week period with concomitant chemotherapy (d 1-5: 20 mg/m2/d DDP + 750-1000 mg/m2/d 5FU (cont. infusion).
  • This therapy block was repeated after a fortnight break up to a cumulative dose of 60 Gy and followed by a boost up to 70 Gy (69-70.5 Gy).
  • RESULTS: Forty patients (63 %) received both radiation and chemotherapy according to the protocol.
  • No patient died of complications, 52 patients (80 %) had acute grade 2-3 mucositis, and 33 patients (58 %) suffered from acute grade 3 skin toxicity.
  • Leucopenia was no major problem (mean nadir 3.4 g/nl, no patient < 1.0 g/nl) and the mean hemoglobin value decreased from 13.2 to 10.5 g/dl.
  • CONCLUSION: The SCHARC protocol was effective in patients diagnosed with advanced head and neck cancer.
  • Most patients were not anemic at beginning of therapy.
  • Therefore, we could assess the influence of pre-treatment hemoglobin on survival.
  • This result suggests an influence of anemia during therapy on prognosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Carcinoma / radiotherapy. Dose Fractionation. Guideline Adherence / statistics & numerical data. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Hemoglobins / analysis
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy / adverse effects. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis. Time. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 May 1;23(13):3008-15 [15860857.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1341-8 [15846296.001]
  • [Cites] Laryngoscope. 2005 Jun;115(6):1015-20 [15933512.001]
  • [Cites] Int J Oncol. 2005 Sep;27(3):669-79 [16077915.001]
  • [Cites] Radiother Oncol. 2005 Aug;76(2):200-5 [16024111.001]
  • [Cites] Melanoma Res. 2005 Oct;15(5):417-25 [16179869.001]
  • [Cites] Lancet Oncol. 2005 Oct;6(10):757-64 [16198981.001]
  • [Cites] Radiother Oncol. 2005 Oct;77(1):18-24 [16098619.001]
  • [Cites] BMC Cancer. 2006;6:28 [16448551.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):459-66 [10661354.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):13-47 [10758303.001]
  • [Cites] Int J Biol Markers. 2000 Jul-Sep;15(3):235-6 [11012100.001]
  • [Cites] Strahlenther Onkol. 2000 Oct;176(10):475-80 [11068594.001]
  • [Cites] Strahlenther Onkol. 2001 Apr;177(4):182-8 [11370552.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):865-72 [11429213.001]
  • [Cites] Strahlenther Onkol. 2001 Sep;177(9):469-73 [11591020.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1000-7 [11844823.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4617-22 [12183417.001]
  • [Cites] Strahlenther Onkol. 2002 Aug;178(8):436-41 [12240549.001]
  • [Cites] Strahlenther Onkol. 2003 Aug;179(8):521-6 [14509950.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Oct;129(10):1110-4 [14568798.001]
  • [Cites] Lancet. 2003 Oct 18;362(9392):1255-60 [14575968.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1418-23 [15050318.001]
  • [Cites] Acta Oncol. 1988;27(2):147-52 [3390345.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1049-91 [7713776.001]
  • [Cites] Radiother Oncol. 1997 Apr;43(1):47-51 [9165136.001]
  • [Cites] Radiother Oncol. 1998 Aug;48(2):157-64 [9783887.001]
  • [Cites] Eur J Cancer. 1998 May;34(6):856-61 [9797698.001]
  • [Cites] Strahlenther Onkol. 1998 Dec;174 Suppl 4:13-6 [9879341.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1999 Jan;108(1):73-8 [9930544.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jul 1;44(4):749-54 [10386631.001]
  • [Cites] Strahlenther Onkol. 2004 Dec;180(12):805-10 [15592701.001]
  • [Cites] Semin Oncol. 2004 Dec;31(6):822-6 [15599861.001]
  • [Cites] Head Neck. 2005 Jan;27(1):36-43 [15459918.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2004;66(6):325-31 [15668532.001]
  • [Cites] Strahlenther Onkol. 2005 Feb;181(2):113-23 [15702300.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1087-95 [15752888.001]
  • [Cites] J Otolaryngol. 2004 Oct;33(5):295-8 [15931813.001]
  • (PMID = 17150114.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hemoglobins; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC1702360
  •  go-up   go-down


Advertisement
4. Kim BJ, Kim DW, Kim SW, Han DH, Kim DY, Rhee CS, Lee CH: Endoscopic versus traditional craniofacial resection for patients with sinonasal tumors involving the anterior skull base. Clin Exp Otorhinolaryngol; 2008 Sep;1(3):148-53

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: With the advent of microdebriders and image guidance systems, endoscope-assisted surgery is now more widely used for the treatment of tumors involving the base of the skull.
  • The aim of this study was to analyze the clinical features of tumors involving the anterior skull base and to evaluate the treatment outcomes according to the surgical approach, which included the traditional craniofacial resection (TCFR) and the endoscopic craniofacial resection with craniotomy (ECFR).
  • METHODS: Forty-six patients who underwent craniofacial resection from 1989 through 2006 at Seoul National University Hospital and Seoul National University Bundang Hospital were included in this study.
  • Demographics, histology, surgical management, surgical outcomes, complications, and morbidity were analyzed.
  • RESULTS: The number of malignant and benign lesions was 40 and 6 cases respectively.
  • The most common diagnosis was olfactory neuroblastoma occurring in 41% of the cases followed by squamous cell carcinoma and malignant melanoma.
  • Thirty-six patients underwent TCFR, while ECFR was performed with or without adjunctive chemotherapy or radiotherapy in 10 patients.
  • The overall five-year survival rate for patients with malignant tumors of the anterior skull base was 47.4%.
  • CONCLUSION: The ECFR may be considered as an alternative option for the treatment of selected tumors with anterior skull base invasion.
  • This approach offers the advantages of avoiding facial incisions with comparable treatment results.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Rhinol. 2007 Jan-Feb;21(1):89-94 [17283568.001]
  • [Cites] Laryngoscope. 2001 Mar;111(3):488-93 [11224781.001]
  • [Cites] Skull Base. 2006 Feb;16(1):15-8 [16880896.001]
  • [Cites] Laryngoscope. 2006 Jun;116(6):982-6 [16735899.001]
  • [Cites] Laryngorhinootologie. 2005 Dec;84(12):884-91 [16358197.001]
  • [Cites] Neurosurg Focus. 2002 May 15;12(5):e4 [16119902.001]
  • [Cites] Otolaryngol Clin North Am. 2005 Feb;38(1):133-44, ix [15649504.001]
  • [Cites] Cancer. 2004 Nov 15;101(10):2257-60 [15484215.001]
  • [Cites] Am J Surg. 1963 Nov;106:698-703 [14078719.001]
  • [Cites] Am J Rhinol. 1999 Jul-Aug;13(4):303-10 [10485018.001]
  • [Cites] Am J Otolaryngol. 1997 Nov-Dec;18(6):431-3 [9395024.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1029-37 [9588547.001]
  • [Cites] Neurosurgery. 1996 Mar;38(3):471-9; discussion 479-80 [8837798.001]
  • [Cites] Head Neck. 1994 Jul-Aug;16(4):307-12 [8056574.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1992 Sep;118(9):913-7 [1503715.001]
  • [Cites] Am J Surg. 1988 Sep;156(3 Pt 1):187-90 [3421426.001]
  • [Cites] Otolaryngol Head Neck Surg. 1989 Dec;101(6):665-9 [2512555.001]
  • [Cites] Am J Surg. 1987 Oct;154(4):352-8 [3661836.001]
  • [Cites] Head Neck Surg. 1986 Jul-Aug;8(6):429-35 [3721885.001]
  • [Cites] Am J Rhinol. 2004 Jul-Aug;18(4):239-46 [15490571.001]
  • [Cites] Laryngoscope. 2003 Dec;113(12):2086-90 [14660907.001]
  • [Cites] Otolaryngol Clin North Am. 2001 Dec;34(6):1123-42, ix [11728937.001]
  • [Cites] Laryngoscope. 2006 Oct;116(10):1749-54 [17003718.001]
  • (PMID = 19434247.001).
  • [ISSN] 1976-8710
  • [Journal-full-title] Clinical and experimental otorhinolaryngology
  • [ISO-abbreviation] Clin Exp Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2671747
  • [Keywords] NOTNLM ; Endoscopic craniofacial resection / Nose neoplasms / Skull base
  •  go-up   go-down


5. Luo D, Xia H: [Clinical and pathological characteristics of head and neck malignant melanoma]. Zhonghua Zhong Liu Za Zhi; 2001 May;23(3):256-8
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical and pathological characteristics of head and neck malignant melanoma].
  • OBJECTIVE: To investigate the clinical and pathological characteristics of head and neck malignant melanoma.
  • METHODS: Sixty-eight cases of head and neck malignant melanoma were reviewed.
  • There were 33 patients with melanoma in the nasal cavity and oral cavity, 35 patients with melanoma in the skin.
  • Surgical specimens in 52 cases and biopsy specimens in 16 cases were studied pathologically.
  • Immunohistochemical studies helped diagnosis as all of the 42 melanoma specimens were posture for S-100 and 90.5% positive for HMB45.
  • In 52 of the 68 cases, the tumor was excised surgically, with additional radiotherapy in 13 cases or chemotherapy in 21 cases.
  • In 56 patients followed-up, 12 survived for 5 years, including 9 cases of skin melanoma and 3 cases of nasal and oral melanoma.
  • CONCLUSION: The histo-pathological features of malignant melanoma vary significantly.
  • Immunohistochemical staining helps diagnosis and differential diagnosis.
  • The prognosis of malignant melanoma in nasal cavity and oral cavity is poor as compared to that in the skin of head and neck region.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Melanoma / pathology. Neoplasm Proteins / analysis. S100 Proteins / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, Neoplasm. Female. Humans. Immunohistochemistry. Male. Melanoma-Specific Antigens. Middle Aged. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11783102.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / S100 Proteins
  •  go-up   go-down


6. Tímár J, Kásler M, Kátai J, Soós M, Mathiasz D, Romány A, Patthy L, Kovács G, Józsa A, Szilák L, Forrai T: [Developments in cancer management by innovative genomics. 2006 report of the National Cancer Consortium]. Magy Onkol; 2006;50(4):349-59
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Developments in cancer management by innovative genomics. 2006 report of the National Cancer Consortium].
  • Research on developing molecular diagnostics for hereditary cancers resulted in establishing diagnostic services for familiar polyposis and non-polyposis patients (mutation determination of APC, MYH, STK11, SMAD4, MLH1, MSH2).
  • Molecular diagnostic tool was established to monitor the progression of follicular lymphoma using Bcl-2/IgH fusion sequences.
  • Molecular diagnostic tools were developed to monitor circulating endothelial precursor cells (CEP) as well and the technique was tested in lung cancer patients.
  • In malignant melanoma we have tested several potential novel markers among which ryanodine receptor seems to be a promising one, while the functional P2X7 receptor may serve as a therapeutic target.
  • We have determined the tyrosine kinase "kinome" profile of HER-2-amplified breast cancers.
  • Furthermore, the "kinome" profile was found to be characteristic for head and neck cancers of various anatomical location.
  • Based on previous studies on the anti-migratory and antimetastatic potential of low-molecular-weight heparins, we have identified short heparin-derived oligosaccharides with maintained antimetastatic- but non-anticoagulant potentials.
  • Pharmacogenomic studies on the role of polymorphism of the serine-hydroxymethyl-transferase (SHMT) gene in the efficacy of 5-FU and FOLFIRI protocols of colorectal cancer patients revealed a significant effect resulting in altered overall survival as well.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Biomarkers, Tumor / genetics. Genomics. Mutation. Neoplasms / diagnosis. Neoplasms / genetics
  • [MeSH-minor] Breast Neoplasms / diagnosis. Breast Neoplasms / genetics. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / genetics. Colorectal Neoplasms, Hereditary Nonpolyposis / diagnosis. Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. Disease Progression. Female. Glycine Hydroxymethyltransferase / genetics. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / genetics. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / genetics. Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / genetics. Male. Melanoma / diagnosis. Melanoma / genetics. Neovascularization, Pathologic / diagnosis. Neovascularization, Pathologic / drug therapy. Pharmacogenetics. Polymorphism, Genetic. Prognosis. Receptors, Purinergic P2 / drug effects. Receptors, Purinergic P2X7. Ryanodine Receptor Calcium Release Channel / drug effects. Testicular Neoplasms / diagnosis. Testicular Neoplasms / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17216011.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / P2RX7 protein, human; 0 / Receptors, Purinergic P2; 0 / Receptors, Purinergic P2X7; 0 / Ryanodine Receptor Calcium Release Channel; EC 2.1.2.1 / Glycine Hydroxymethyltransferase
  • [Number-of-references] 15
  •  go-up   go-down


7. Hashemi M, Stark A, Hugo H, Mehdorn M: Intracranial trigeminal nerve metastasis of a desmoplastic neurotropic melanoma: case report. Cent Eur Neurosurg; 2009 May;70(2):91-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial trigeminal nerve metastasis of a desmoplastic neurotropic melanoma: case report.
  • BACKGROUND: Desmoplastic neurotropic mela-noma is a rare and highly malignant variant of melanoma.
  • Solitary nervus trigeminus and Gasserian ganglion metastasis of a neurotropic melanoma has not been previously described in the literature.
  • 4 years previously he underwent tumor removal with an initial diagnosis of amelanotic malignant cutaneous melanoma; 1 year later, because of tumor recurrence, the patient underwent neck dissection, chemotherapy and radiation.
  • Magnet resonance imaging (MRI) disclosed an enhancement of the Gasserian ganglion and tumor extension along the mandibular and maxillar nerves of the intracranial part of the trigeminal nerve suggestive of tumor.
  • The intraoperative macroscopic appearance of the tumor was compatible with a neurinoma.
  • Histopathological studies proved the tumor to be a desmoplastic neurotropic melanoma (DNM) that was related to the previously treated malignant melanoma.
  • CONCLUSION: A metastatic tumor arising solely in a trigeminal nerve from a cutaneous malignant melanoma is quite rare; to our knowledge this may be the first report of such a case in the literature.
  • [MeSH-major] Cranial Nerve Neoplasms / secondary. Melanoma / secondary. Skin Neoplasms / pathology. Trigeminal Nerve. Trigeminal Nerve Diseases / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) Georg Thieme Verlag KG Stuttgart, New York.
  • (PMID = 19711263.001).
  • [ISSN] 1868-4904
  • [Journal-full-title] Central European neurosurgery
  • [ISO-abbreviation] Cent Eur Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


8. Tímár J, Nemzeti Onkológiai Kutatás-fejlesztési Konzorcium: [Activity of the National Oncology R&D Consortium in 2004]. Magy Onkol; 2005;49(1):3-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have prepared the map of regional distribution of cervical cancer in Hungary.
  • A cost-effective molecular staging method was introduced to the management of breast cancer patients.
  • Genomic profiling identified the gene signature of Herceptin and taxane sensitivity of breast cancer.
  • In colon cancer patients we have determined the mutational spectrum of hMLH1 and hMSH2 genes in Hungary.
  • The prognostic power of SHMT and MTHFR polymorphism was determined in colorectal cancer patients.
  • In head and neck cancer the gene signature of cisplatin sensitivity and the EGFR polymorphism was determined.
  • We have introduced a cost-effective in vitro assay to determine the drug resistance of pediatric leukemias.
  • A phase I trial for gene therapy of brain cancer was started by using a GM-CSF adenoviral vector system.
  • Using global genomic approaches the gene signature of malignant melanoma and its metastatic disease was determined.
  • We have found that Ca-channel blockers and EGFR tyrosine kinase inhibitors are effective in preclinical human melanoma models in breaking the apoptosis resistance of this tumor.
  • [MeSH-minor] Breast Neoplasms / diagnosis. Breast Neoplasms / epidemiology. Breast Neoplasms / genetics. Breast Neoplasms / therapy. Colonic Neoplasms / diagnosis. Colonic Neoplasms / epidemiology. Colonic Neoplasms / genetics. Colonic Neoplasms / therapy. Disease Progression. Female. Government Agencies. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / epidemiology. Head and Neck Neoplasms / genetics. Head and Neck Neoplasms / therapy. Humans. Hungary. Journalism, Medical. Male

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15902326.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Hungary
  • [Number-of-references] 32
  •  go-up   go-down


9. Ogawa T, Nakayama B, Hasegawa Y, Fujimoto Y, Kohmura T, Matsuura H, Miyata H: Treatment of malignant melanoma of the lower eyelid using anterolateral thigh flap. Auris Nasus Larynx; 2000 Jan;27(1):79-82
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of malignant melanoma of the lower eyelid using anterolateral thigh flap.
  • Malignant melanoma is a poor prognostic disease with the potential for high mortality despite early diagnosis and currently available treatment.
  • Surgical judgment pertaining to the extent of primary resection and regional node dissections must be tempered by cosmetic considerations and by the anatomically diffuse pathways for lymphatic spread in certain lesions.
  • We reported a case of malignant melanoma of the left lower eyelid, and presented the surgical excision and reconstruction using anterolateral thigh flap for skin defect.
  • It is evident that comprehensive treatment using radical surgery and adjuvant chemotherapy is necessary for cutaneous malignant melanoma of head and neck areas.
  • [MeSH-major] Eyelid Neoplasms / surgery. Melanoma / surgery. Skin Transplantation / methods. Surgical Flaps. Thigh
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Humans. Male. Postoperative Care. Reconstructive Surgical Procedures / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10648074.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] NETHERLANDS
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


10. Murayama K, Takita H, Kiyohara Y, Shimizu Y, Tsuchida T, Yoneya S: [Melanoma-associated retinopathy with unknown primary site in a Japanese woman]. Nippon Ganka Gakkai Zasshi; 2006 Mar;110(3):211-7
MedlinePlus Health Information. consumer health - Retinal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Melanoma-associated retinopathy with unknown primary site in a Japanese woman].
  • BACKGROUND: We report the clinical features of the first case of a Japanese person with melanoma-associated retinopathy.
  • After one month of treatment, she still complained of photopsia in her right eye.
  • A full-field electroretinogram demonstrated a negative-type electroretinogram (ERG) waveform with attenuation of the b-wave amplitude in the right eye.
  • The lymph nodes on the right side of her neck were examined and the diagnosis was made of metastic cutaneous melanoma with unknown primary site; her visual dysfunction was diagnosed as melanoma-associated retinopathy.
  • The retinal inflammation improved after steroid treatment, but her visual dysfunction remained.
  • Chemotherapy and an immunotherapy regimen was begun, but 36 months later she died of metastatic melanoma in the lungs.
  • CONCLUSIONS: A woman treated for uveitis without any prior systemic and ocular diseases was diagnosed with melanoma-associated retinopathy and metastatic melanoma in the cervical lymph nodes of unknown primary origin.
  • The first ocular symptoms were photopsia and blurred vision, not night blindness.
  • ERG was useful for diagnosing this rare ocular condition in an early stage.
  • [MeSH-major] Melanoma / secondary. Neoplasms, Unknown Primary. Retinal Diseases / etiology
  • [MeSH-minor] Adult. Electroretinography. Female. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Neck

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16562510.001).
  • [ISSN] 0029-0203
  • [Journal-full-title] Nippon Ganka Gakkai zasshi
  • [ISO-abbreviation] Nippon Ganka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


11. Daryanani D, Plukker JT, de Jong MA, Haaxma-Reiche H, Nap R, Kuiper H, Hoekstra HJ: Increased incidence of brain metastases in cutaneous head and neck melanoma. Melanoma Res; 2005 Apr;15(2):119-24
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased incidence of brain metastases in cutaneous head and neck melanoma.
  • The incidence of cutaneous melanoma is increasing, and 10-20% of these melanomas are located in the head and neck region.
  • The incidence of brain metastases, risk factors and outcome were analysed for melanomas originating in the head and neck region.
  • During the period 1965-2000, 324 patients [152 females (47%), 172 males (53%)] were treated for cutaneous melanoma of the head and neck.
  • The patients were staged according to the 2002 American Joint Committee on Cancer (AJCC) melanoma staging system.
  • Twenty six (8%) head and neck patients, compared with 5.2% of extremity/truncal patients, developed brain metastases (confidence interval, 0.058-0.108; P<0.05).
  • The 26 head and neck patients (four Stage I, 10 Stage II and 12 Stage III) had a median age of 46 years (range, 16-79 years) and developed brain metastases after a median follow-up of 24 months (range, 4-75 months).
  • The patients were treated with steroids, surgery, radiation, chemotherapy, or a combination of these.
  • Risk factors identified for the development of brain metastases from head and neck melanoma were a younger age, male gender, Breslow thickness greater than 4 mm and increased mitotic rate.
  • The incidence of brain metastases is significantly higher in patients with cutaneous melanoma of the head and neck (8%) compared with those with extremity/truncal melanoma (5.2%).
  • The prognosis is still extremely poor with current therapies.
  • [MeSH-major] Brain Neoplasms / secondary. Head and Neck Neoplasms / pathology. Melanoma / secondary. Skin Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Incidence. Lymph Node Excision. Lymphatic Metastasis / diagnosis. Male. Middle Aged. Neoplasm Staging. Prognosis. Regression Analysis. Risk Factors. Sex Factors. Survival Analysis


12. Schwipper V: [Malignant melanoma in the area of the head and neck]. Mund Kiefer Gesichtschir; 2000 May;4 Suppl 1:S177-86
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant melanoma in the area of the head and neck].
  • [Transliterated title] Malignes Melanom der Kopf-Hals-Region.
  • Malignant melanoma is one of the most frequent malignancies of the skin.
  • This is particularly true of malignant melanoma in juveniles.
  • At Fachklinik Hornheide, a tumor center specializing in skin neoplasm with patients being referred from all over Germany, the number of melanoma patients treated per year has been approximately 500-550 for the past 10 years.
  • In the present study, the state-of-the-art therapy for primary melanoma and treatment of the regional lymph node system is discussed.
  • The radical treatment formerly advocated with wide tumor resection plus radical neck dissection is no longer justified for this immunogenic malignant tumor caused by endogenic as well as exogenic factors.
  • "Sentinel lymph node" imaging by means of radioactive substances for diagnosing possible melanoma metastases in adjacent lymph nodes has changed the therapeutical concept.
  • Tumor staging by means of ultrasound, CT, MRT, or PET allows the differentiation of tumors without distant metastases and a favorable prognosis, from melanomas which have to be considered as generalized disease.
  • In addition to surgical resection of the tumor and neck dissection for removal of lymph nodes, adjuvant immunotherapy with interferon-alpha is capable of prolonging survival without a recurrence.
  • Palliative chemotherapy or immunotherapy are valuable options for cases with generalized melanoma.
  • Vaccination with a melanoma-associated antigen or dendritic cells is at an experimental stage and may become part of future treatment strategies.
  • [MeSH-major] Head and Neck Neoplasms / therapy. Melanoma / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10938658.001).
  • [ISSN] 1432-9417
  • [Journal-full-title] Mund-, Kiefer- und Gesichtschirurgie : MKG
  • [ISO-abbreviation] Mund Kiefer Gesichtschir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 43
  •  go-up   go-down


13. Slavícek A, Astl J, Válková D, Betka J, Petruzelka L: [Malignant mucosal melanoma of the head and neck]. Sb Lek; 2000;101(4):315-23
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant mucosal melanoma of the head and neck].
  • [Transliterated title] Maligní melanom sliznic hlavy a krku.
  • Mucosal melanoma comparison to cutaneous melanoma of the head and neck are rare and do poorly.
  • Approximately 0.5-2% of all melanomas occur from the mucous membranes of aerodigestive tract.
  • Most common site of the tumor are the nasal cavity and paranasal sinuses but melanoma of the oral cavity are described too.
  • Therapy usually consists of surgical resection with or without postoperative radiotherapy and immunochemotherapy eventually.
  • The definite role of a kind of therapy in the treatment of mucosal melanoma is not remains to be defined as the small number of cases make prospective study challenging.
  • This article reviews 19 patients with mucosal melanoma of the head and neck treated at the Department of ENT and Head and Neck Surgery Charles University of Prague since 1980 to 1999.
  • Clinical data were obtained from the patient's charts.
  • Analysis of the metastatic disease, type of therapy and follow-up was retrospectively reviewed.
  • The site of the tumor was the lateral wall of the nasal cavity (five cases), nasal septum (four cases), maxilar cavity (two cases), and ethmoidal cavity, orbitoethmoidal complex, nasopharynx, saccus lacrimalis to ethmoidal sinuses diffused, tonsilla (one case each) and hypopharynx (two cases).
  • Primary treatment was surgical resection in ten cases, in one case with radiation therapy, and in seven cases chemotherapy.
  • In three cases were diagnostic surgery only and one patient was without therapy.
  • Three patients received radical neck dissection more.
  • Four patients were treated radiation therapy and three chemotherapy after surgery.
  • For nine cases of recurrence of the disease were surgery (in five cases) and chemotherapy (in four cases).
  • Overal and disease free interval was from 2 to 22 month, approximately 9.3 month and 3-year survival was 41.18%.
  • [MeSH-major] Melanoma. Mucous Membrane. Otorhinolaryngologic Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11702570.001).
  • [ISSN] 0036-5327
  • [Journal-full-title] Sborník lékar̆ský
  • [ISO-abbreviation] Sb Lek
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  •  go-up   go-down


14. Bradley PJ: Primary malignant mucosal melanoma of the head and neck. Curr Opin Otolaryngol Head Neck Surg; 2006 Apr;14(2):100-4
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant mucosal melanoma of the head and neck.
  • PURPOSE OF REVIEW: Primary malignant melanoma of the head and neck is an uncommon disease associated with a very poor prognosis, and an unpredictable natural disease process.
  • Most patients, when diagnosed, pose a major dilemma to their treating clinicians as to what is the most appropriate current management options available with their likely short-term or long-term results.
  • RECENT FINDINGS: Not much new has been reported in terms of aetiology and biology.
  • There have been proposals for improvements in staging disease at presentation, so as to permit better analysis of results.
  • Surgery continues to be advocated as the treatment option of choice.
  • The role of radiotherapy as primary management of mucosal malignant melanoma remains controversial, but its use following surgery does seem to achieve local tumour control and patient survival.
  • The use of chemotherapy or immunotherapy in mucosal malignant melanoma continues to lack structure and a role.
  • Patients presenting with mucosal malignant melanoma should be registered and entered into a national or even international randomized controlled trial, which includes surgery, radiotherapy and immunotherapy.
  • SUMMARY: Primary malignant mucosal melanoma of the head and neck is rare.
  • The current standard of treatment remains surgery with postoperative radiotherapy.
  • Such treatment aims at local disease control, with close follow-up observation and salvage treatment for local, regional and disseminated disease if it occurs.
  • Salvage treatments are rare and uncommon, and most do not result in any significant additional patient survival.
  • The role of chemotherapy and immunotherapy remains speculative unless patients are entered into some form of randomized controlled trials.
  • [MeSH-major] Head and Neck Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Melanoma / etiology. Melanoma / pathology. Melanoma / therapy. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16552267.001).
  • [ISSN] 1068-9508
  • [Journal-full-title] Current opinion in otolaryngology & head and neck surgery
  • [ISO-abbreviation] Curr Opin Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 38
  •  go-up   go-down


15. Wang H, Zhan W, Chen H, Xu J: [Sinonasal malignant melanoma: 24 cases report]. Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2006 Jan;20(1):21-2
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sinonasal malignant melanoma: 24 cases report].
  • OBJECTIVE: To review the pathological and clinical features and treatment of sinonasal malignant melanoma.
  • METHOD: Twenty-four patients with sinonasal malignant melanoma were surgically treated, 18 cases were treated with lateral rhinotomy, two cases with partial maxillectomy and ligation of external carotid artery, two cases with Caldwell-Luc technique,two cases with craniofacial approach, four cases with neck dissection.
  • Among them, 14 patients were only treated by operation, eight cases by operation and radiotherapy, two cases combined by operation, radiotherapy and chemotherapy.
  • RESULT: Twenty-two patients were followed up, the survival rates of 3 and 5 years were 54.5% (12/22) and 31.8% (7/22), respectively.
  • CONCLUSION: Sinonasal malignant melanoma has an aggressive behavior and easy recurrence.
  • Early diagnosis and radical operation can improve the survival rate.
  • [MeSH-major] Melanoma. Paranasal Sinus Neoplasms. Skin Neoplasms

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16548152.001).
  • [Journal-full-title] Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology
  • [ISO-abbreviation] Lin Chuang Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


16. Bergman K, Murphy R, Miller M: Cervical thymic rebound after cancer treatment. J Pediatr Surg; 2005 Jul;40(7):1188-90
Genetic Alliance. consumer health - Cervical cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical thymic rebound after cancer treatment.
  • While newly recognized neck masses in children previously treated for malignancy raise the specter of recurrent disease, recent experience with 2 patients has shown us that enlargement of cervical thymic tissue should be considered in the differential diagnosis, especially early after the completion of chemotherapy or immunotherapy.
  • [MeSH-major] Choristoma. Neck / pathology. Thymus Gland
  • [MeSH-minor] Child. Child, Preschool. Diagnosis, Differential. Humans. Kidney Neoplasms / surgery. Male. Melanoma / drug therapy. Melanoma / surgery. Neoplasm Recurrence, Local / diagnosis. Skin Neoplasms / drug therapy. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16034769.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Aygenç E, Dakak Y, Ozdem C: [A case of auricular malignant melanoma]. Kulak Burun Bogaz Ihtis Derg; 2002 Jan-Feb;9(1):63-5
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of auricular malignant melanoma].
  • [Transliterated title] Auriküler malign melanoma.
  • We performed auricular excision, total parathyroidectomy, and extended radical neck dissection in a 36-year-old male patient who developed auricular malignant melanoma.
  • Reconstruction of the surgical defect was made with a split-thickness skin graft.
  • The patient received radiotherapy and chemotherapy after surgery.
  • [MeSH-major] Ear Neoplasms / surgery. Melanoma / surgery
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Diagnosis, Differential. Ear, External / surgery. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Neck Dissection. Parathyroidectomy. Radiotherapy, Adjuvant. Reconstructive Surgical Procedures. Skin Transplantation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12122628.001).
  • [ISSN] 1300-7475
  • [Journal-full-title] Kulak burun boğaz ihtisas dergisi : KBB = Journal of ear, nose, and throat
  • [ISO-abbreviation] Kulak Burun Bogaz Ihtis Derg
  • [Language] tur
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


18. Maier H, Mühlmeier G, Kraft K, Blumstein NM, Tisch M: [Primary malignant melanoma of the parotid gland: a case report and review of the literature]. HNO; 2008 Jun;56(6):627-32
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary malignant melanoma of the parotid gland: a case report and review of the literature].
  • [Transliterated title] Primäres malignes Melanom in der Glandula parotidea: Fallbericht und Literaturübersicht.
  • Malignant melanomas (MMs) of the parotid gland are relatively uncommon.
  • It is assumed that they originate in the glandular tissue or in intraglandular lymph nodes.
  • We present a case report and review of the literature on the diagnosis, treatment, and prognosis of intraparotid malignant melanoma.
  • Diagnosis is based primarily on B-scan ultrasonography and fine-needle aspiration cytology.
  • Patients with a cytological diagnosis of MM are further evaluated by magnetic resonance imaging and positron emission tomography and receive a thorough ear-nose-throat and dermatological examination.
  • The treatment of choice is total parotidectomy and selective neck dissection.
  • The effectiveness of adjuvant treatments such as radiotherapy, chemotherapy, or immunotherapy remains controversial.
  • Patients with primary MMs of the parotid gland appear to have a better prognosis than those with parotid metastases from melanomas of the skin or mucous membranes.
  • [MeSH-major] Melanoma / diagnosis. Melanoma / therapy. Parotid Neoplasms / diagnosis. Parotid Neoplasms / therapy
  • [MeSH-minor] Humans. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] HNO. 2006 Mar;54(3):166-70 [16091908.001]
  • [Cites] Head Neck. 1997 Oct;19(7):589-94 [9323147.001]
  • [Cites] Laryngoscope. 1994 Oct;104(10):1194-8 [7934587.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1994 Apr;19(2):161-5 [8026097.001]
  • [Cites] Surg Gynecol Obstet. 1963 Sep;117:341-5 [14080349.001]
  • [Cites] Arch Surg. 1997 May;132(5):553-6 [9161401.001]
  • [Cites] Br J Plast Surg. 2001 Oct;54(7):636-7 [11583503.001]
  • [Cites] Am J Surg. 1985 Oct;150(4):510-2 [4051118.001]
  • [Cites] Laryngol Rhinol Otol (Stuttg). 1984 Jan;63(1):17-20 [6700327.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2001;13(6):466-9 [11824888.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1961 Jan;14:108-16 [13708292.001]
  • [Cites] Laryngorhinootologie. 2005 Jul;84(7):516-9 [16010634.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1999 Jun;125(6):635-9 [10367919.001]
  • [Cites] Pathol Int. 1997 Aug;47(8):581-3 [9293542.001]
  • [Cites] Br J Oral Maxillofac Surg. 1993 Oct;31(5):313-5 [8218087.001]
  • [Cites] Tumori. 1999 Nov-Dec;85(6):523-5 [10774579.001]
  • [Cites] J Am Coll Surg. 1995 Sep;181(3):193-201 [7670677.001]
  • [Cites] Cancer. 2000 Dec 25;90(6):350-6 [11156518.001]
  • [Cites] In Vivo. 1998 Nov-Dec;12(6):571-8 [9891219.001]
  • [Cites] Head Neck. 2001 Sep;23(9):744-8 [11505484.001]
  • [Cites] Arch Surg. 1963 Jul;87:6-12 [14031784.001]
  • [Cites] HNO. 2000 Jun;48(6):421-9 [10929222.001]
  • [Cites] Eur J Surg Oncol. 1990 Feb;16(1):28-32 [2307240.001]
  • [Cites] Otolaryngol Head Neck Surg. 1995 Jun;112(6):700-6 [7777355.001]
  • [Cites] J Laryngol Otol. 1990 Apr;104(4):350-1 [2370460.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2002 Jul-Aug;64(4):297-9 [12232480.001]
  • [Cites] Am J Otolaryngol. 1996 Mar-Apr;17(2):102-5 [8820184.001]
  • (PMID = 18066514.001).
  • [ISSN] 1433-0458
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 28
  •  go-up   go-down


19. Reske SN, Kotzerke J: FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000. Eur J Nucl Med; 2001 Nov;28(11):1707-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Positron emission tomography (PET) is the most powerful molecular imaging technique currently available for clinical use.
  • Because deranged tumour metabolism is a common finding in many malignancies, PET is frequently used for tissue characterisation, staging and therapy control.
  • A questionnaire comprising 24 items was developed for standardised quality assessment according to evidence-based medicine (EBM) criteria.
  • Clinical use was judged according to the following grading scheme: 1a, established clinical use; 1b, clinical use probable; 2, useful in individual cases; 3, not yet assessable owing to missing or incomplete data; 4, clinical use rare (either as inferred from theoretical considerations or as demonstrated by published studies).
  • The results of these studies were tabulated and are available at www.nucmed-ulm.de.
  • Clinical indications (grade 1a or 1b) were established for differentiating benign from malignant lesions in pulmonary nodules, pancreatic masses and residual masses after chemotherapy in malignant lymphoma.
  • Staging was improved by FDG-PET in oesophageal cancer, breast cancer, head and neck cancer, lung cancer, malignant lymphoma and malignant melanoma.
  • Effectiveness of radio- and/or chemotherapy could be better controlled in Hodgkin's disease and high-grade non-Hodgkin's lymphoma.
  • Restaging was improved in relapsing thyroid cancer, colorectal cancer, head and neck cancer, lung cancer and malignant melanoma.
  • In summary, the efficiency of FDG-PET was studied in several thousand patients with malignant tumours and was found to be well documented in the international high-quality peer-reviewed literature.
  • There are clear-cut clinical indications for FDG-PET in diagnosis, staging and therapy control, and the technique can help to improve the management of many patients with cancer.
  • [MeSH-major] Fluorodeoxyglucose F18. Neoplasms / radionuclide imaging. Radiopharmaceuticals. Tomography, Emission-Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11702115.001).
  • [ISSN] 0340-6997
  • [Journal-full-title] European journal of nuclear medicine
  • [ISO-abbreviation] Eur J Nucl Med
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 182
  •  go-up   go-down


20. Weisz B, Meirow D, Schiff E, Lishner M: Impact and treatment of cancer during pregnancy. Expert Rev Anticancer Ther; 2004 Oct;4(5):889-902
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact and treatment of cancer during pregnancy.
  • Cancer is the second most common cause of death in the reproductive years and complicates up to one in 1000 pregnancies.
  • When cancer is diagnosed during pregnancy, the management strategy must take into account both the mother and developing fetus.
  • In this article, the four most common malignancies diagnosed in pregnant patients--cervical and breast cancer, malignant melanoma and lymphoma--will be reviewed, with an emphasis on the impact of the diagnosis and management on the pregnant patient and the developing fetus.
  • [MeSH-major] Pregnancy Complications, Neoplastic / drug therapy. Pregnancy Complications, Neoplastic / radiotherapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / radiotherapy. Female. Fetal Development. Humans. Lymphoma / drug therapy. Lymphoma / radiotherapy. Melanoma / drug therapy. Melanoma / radiotherapy. Pregnancy. Risk Factors. Skin Neoplasms / drug therapy. Skin Neoplasms / radiotherapy. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15485322.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 158
  •  go-up   go-down


21. Ma SQ, Bai CM, Yu XH, An YT, Lang JH: [Primary malignant melanoma of the cervix: report of four cases and review of the literature]. Zhonghua Fu Chan Ke Za Zhi; 2005 Mar;40(3):183-5
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary malignant melanoma of the cervix: report of four cases and review of the literature].
  • OBJECTIVE: To investigate the clinical and pathological characteristics of primary cervical malignant melanoma, the treatment, and prognosis.
  • METHODS: The clinical and pathological data of four patients with primary malignant melanoma of the cervix admitted to our hospital from Sept.
  • Nerve tissue protein S-100 and monoclonal antibody to melanoma (HMB-45) were examined in all cases by immunohistochemical method.
  • In addition, three of them received chemotherapy, and one received immunotherapy simultaneously.
  • One patient died six months and another 41 months after the operation respectively.
  • One patient survived for 3 years, and another over 6 years free of tumor.
  • CONCLUSIONS: The prognosis of primary malignant melanoma of cervix is relatively poor.
  • S-100 protein and HMB-45 play important roles in the diagnosis of primary malignant melanoma of cervix.
  • Radical hysterectomy, chemotherapy combined with dimethyl triazemo imidazole carboxamide (DTIC) and immunotherapy can improve the prognosis if the disease could be diagnosed in early stage.
  • [MeSH-major] Melanoma / therapy. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Antigens, Neoplasm / genetics. Antigens, Neoplasm / metabolism. Female. Follow-Up Studies. Gene Expression Regulation, Neoplastic. Humans. Melanoma-Specific Antigens. Middle Aged. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Retrospective Studies. S100 Proteins / genetics. S100 Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15840314.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / S100 Proteins
  •  go-up   go-down


22. Moser C, Furrer J, Ruggieri F: [Neck pain and fever after peginterferon alpha-2a]. Praxis (Bern 1994); 2007 Feb 7;96(6):205-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neck pain and fever after peginterferon alpha-2a].
  • A 39-year-old woman presented to the emergency room with fever and tender swollen neck two days after the first injection of Peginterferon alpha-2a (Pegasys).
  • She had been under Interferon therapy for melanoma over the last five months.
  • We suspected she had a Peginterferon alpha-2a induced thyroiditis de Quervain and started a therapy with NSAR and thereafter with Prednison 20 mg.
  • Not known is, to our knowledge, an acute thyroiditis as a side effect of treatment with Peginterferon alpha-2a.
  • Our case shows that also Peginterferon alpha-2a can induce an inflammation of the thyroid similar to de Quervain's thyroiditis.
  • [MeSH-major] Fever of Unknown Origin / etiology. Interferon-alpha / adverse effects. Melanoma / drug therapy. Neck Pain / etiology. Polyethylene Glycols / adverse effects. Skin Neoplasms / drug therapy. Thyroiditis, Subacute / chemically induced
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Humans. Recombinant Proteins. Thigh

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17330412.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 0 / peginterferon alfa-2a; 30IQX730WE / Polyethylene Glycols; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


23. Ma SQ, Bai CM, Zhong S, Yu XH, Lang JH: Clinical analysis of primary malignant melanoma of the cervix. Chin Med Sci J; 2005 Dec;20(4):257-60
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical analysis of primary malignant melanoma of the cervix.
  • OBJECTIVE: To investigate the clinical and pathological characteristics of primary cervical malignant melanoma, and its prognosis.
  • METHODS: The clinical and pathological data of four patients with primary malignant melanoma of the cervix were analyzed retrospectively.
  • Nerve tissue protein S-100 and monoclonal antibody to melanoma (HMB-45) were measured in all cases by immunohistochemical method.
  • Three of them received chemotherapy preoperation or postoperation, and one of them received biotherapy with interferon-gamma and interleukin-2 at the same time.
  • All the four cases were pathologically diagnosed with cervical malignant melanoma.
  • CONCLUSIONS: S-100 protein and HMB-45 play very important roles in the diagnosis of primary malignant melanoma of cervix.
  • Radical hysterectomy, chemotherapy combined with dimethyl triazemo imidazole carboxamide and biological therapies may improve the prognosis of the primary malignant melanoma of cervix if the disease could be diagnosed in an early stage.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16422255.001).
  • [ISSN] 1001-9294
  • [Journal-full-title] Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
  • [ISO-abbreviation] Chin. Med. Sci. J.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / S100 Proteins; 7GR28W0FJI / Dacarbazine; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


24. Sciubba JJ: Oral cancer. The importance of early diagnosis and treatment. Am J Clin Dermatol; 2001;2(4):239-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral cancer. The importance of early diagnosis and treatment.
  • Oral cancer is an important health issue.
  • The WHO predicts a continuing worldwide increase in the number of patients with oral cancer, extending this trend well into the next several decades.
  • In the US the projected number of new cases of oral and oropharyngeal cancer will exceed 31,000 per year.
  • Mortality due to cancers in this region exceeds the annual death rate is the US caused by either cutaneous melanoma or cervical cancer.
  • Significant agents involved in the etiology of oral cancer in Western countries include sunlight exposure, smoking and alcohol consumption.
  • Recently, strong evidence for an etiological relationship between human papilloma virus and a subset of head and neck cancers has been noted.
  • It is generally accepted that most sporadic tumors are the result of a multi-step process of accumulated genetic alterations.
  • These alterations affect epithelial cell behavior by way of loss of chromosomal heterozygosity which in turn leads to a series of events progressing to the ultimate stage of invasive squamous cell carcinoma.
  • Proliferative verrucous leukoplakia represents a relatively new type of leukoplakia that is separate from the more common or less innocuous form of this condition.
  • Squamous cell carcinoma will develop from antecedent dysplastic oral mucosal lesions if an early diagnosis has not been made and treatment given.
  • Early diagnosis within stages I and II correspond to a vastly improved 5-year survival rate when compared with more advanced stage III and IV lesions.
  • Surgical management of this disease remains the mainstay of treatment.
  • Other therapies include radiation and chemotherapy options that may be used adjunctively and palliatively.
  • Following treatment, it is important to understand the significant risks of second primary cancers developing within the upper aerodigestive tract as a result of field cancerization.
  • The most important message is that early detection of the asymptomatic early stage oral cancer translates in general terms to satisfactory clinical outcome and cure in most patients.
  • [MeSH-minor] Biopsy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Carcinoma, Squamous Cell / therapy. Carcinoma, Verrucous / diagnosis. Carcinoma, Verrucous / pathology. Carcinoma, Verrucous / surgery. Carcinoma, Verrucous / therapy. Combined Modality Therapy. Diagnosis, Differential. Humans. Leukoplakia, Oral / diagnosis. Leukoplakia, Oral / pathology. Leukoplakia, Oral / surgery. Leukoplakia, Oral / therapy. Neoplasm Staging. Palatal Neoplasms / diagnosis. Palatal Neoplasms / pathology. Palatal Neoplasms / surgery. Palatal Neoplasms / therapy. Palliative Care. Prognosis. Risk Factors. Time Factors. Tongue / pathology. Tongue Neoplasms / diagnosis. Tongue Neoplasms / pathology. Tongue Neoplasms / surgery. Tongue Neoplasms / therapy. World Health Organization

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11705251.001).
  • [ISSN] 1175-0561
  • [Journal-full-title] American journal of clinical dermatology
  • [ISO-abbreviation] Am J Clin Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Number-of-references] 39
  •  go-up   go-down


25. Nohara T, Sakai A, Fuse H, Imamura Y: [Metastatic malignant melanoma of the urinary bladder: a case report]. Nihon Hinyokika Gakkai Zasshi; 2009 Nov;100(7):707-11
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastatic malignant melanoma of the urinary bladder: a case report].
  • A 62-year-old male underwent resection of malignant melanoma of left breast skin in 2006.
  • In 2007, he underwent lymph node dissection and chemotherapy (DAV-feron therapy) for left axillary lymph nodes metastasis.
  • Two non-papillary bladder tumors were detedted on cystoscopy and CT/ MRI showed multiple lymph node swelling, including left inguinal, paraaortic, and right cervical regions.
  • As malignant melanoma cells were found on urinary cytology, a diagnosis of metastatic malignant melanoma of the urinary bladder was made.
  • It was thought that tumor resection would not contribute to prognostic improvement because of multiple lymph node metastases.
  • Therefore, tumor resection was not performed.
  • The patient is currently receiving chemotherapy.
  • This is the eleventh case of metastatic malignant melanoma of the urinary bladder to be reported in the Japanese literature.
  • There have been no previous reports of cases in which urinary cytology was positive for malignant melanoma cells.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Melanoma / drug therapy. Melanoma / secondary. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / secondary
  • [MeSH-minor] Dacarbazine / administration & dosage. Humans. Interferon-beta / administration & dosage. Lymphatic Metastasis. Male. Middle Aged. Nimustine / administration & dosage. Skin Neoplasms / pathology. Skin Neoplasms / therapy. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19999137.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0S726V972K / Nimustine; 5J49Q6B70F / Vincristine; 77238-31-4 / Interferon-beta; 7GR28W0FJI / Dacarbazine; DAV protocol
  • [Number-of-references] 9
  •  go-up   go-down


26. Yücesoy G, Kus E, Cakiroglu Y, Muezzinoglu B, Yildiz K, Yucesoy I: Primary malignant melanoma of the cervix: report of a case. Arch Gynecol Obstet; 2009 Apr;279(4):573-5
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant melanoma of the cervix: report of a case.
  • BACKGROUND: To present a case of primary malignant melanoma of the cervix.
  • CASE: The patient was admitted with the complaint of vaginal bleeding.
  • Histopathology showed a malignant neoplasm with increased vascularity, indicating the possibility of a primary uterine cervical melanoma.
  • Diagnosis of malignant melanoma was confirmed with immunohistochemistry, which showed diffuse positive reactions for S-100 protein and HBM-45, with no reaction for epithelial markers, namely cytokeratin AE1/AE3 and epithelial membrane antigen.
  • An extensive search for a melanotic lesion in skin and in uveal tract was performed to verify the distinct site of melanoma.
  • The tumor was stage IB1 according to the International Federation of Gynecology and Obstetrics classification.The patient underwent radical Wertheim-Meigs hysterectomy, bilateral salpingo-oopherectomy, and retroperitoneal pelvic lympadenectomy.
  • Radiotherapy or chemotherapy was not performed in the postoperative period.
  • CONCLUSION: Primary malignant melanoma of the cervix is a rare cervical malignancy.
  • [MeSH-major] Melanoma / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Female. Gynecologic Surgical Procedures. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18726108.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


27. Huang Q, Wu H, Wang Z, Zhang Z, Jia H: [Diagnosis and treatment of lateral skull base tumors in pediatric]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2008 Aug;22(16):734-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of lateral skull base tumors in pediatric].
  • OBJECTIVE: To explore the diagnosis and treatment of lateral skull base tumors in children.
  • METHOD: The clinical data of 8 patients with lateral skull base tumors were reviewed in a retrospective study.
  • One had schwannoma of the trigeminal nerve, one had malignant melanoma, one had fibroma in temporal bone, one had chordoma, two had rhabdomyosarcoma, two had esthesioneuroblastoma.
  • Of 8 patients, one case was treated with chemotherapy.
  • The other 7 cases of benign or malignant tumors underwent surgery in different approaches.
  • Four patients had pre-and postoperative chemotherapy.
  • Three patients received postoperative chemotherapy.
  • RESULT: The group patients had been followed up for 1-1.5 years and it was shown that there was no recurrence in 4 cases, while there was recurrence in 4 cases.
  • One patient of chordoma died 5 months after surgery, the other 7 patients were alive at the time of analysis.
  • Hearing loss occurred in one patient in the operated ear.
  • One patient developed hoarseness.
  • Two patients developed swallowing obstruction and healed 3-4 months after surgery.
  • CONCLUSION: Tumors in lateral skull base in children were rare, of which malignant tumors were more common compared to benign lesions.
  • Surgery is the first choice of the treatment for lateral skull base tumors.
  • Radiation therapy and chemotherapy could be used for malignant tumors preoperatively and postoperatively.
  • Combined approach of temporal and infratemporal fossa is suitable for the surgery of those tumors involved temporal bone and middle or posterior cranial fossa as well as infratemporal fossa.
  • [MeSH-major] Skull Base Neoplasms / diagnosis. Skull Base Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18975775.001).
  • [ISSN] 1001-1781
  • [Journal-full-title] Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery
  • [ISO-abbreviation] Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


28. Ganly I, Patel SG, Singh B, Kraus DH, Bridger PG, Cantu G, Cheesman A, De Sa G, Donald P, Fliss DM, Gullane P, Janecka I, Kamata SE, Kowalski LP, Levine PA, Medina dos Santos LR, Pradhan S, Schramm V, Snyderman C, Wei WI, Shah JP: Craniofacial resection for malignant melanoma of the skull base: report of an international collaborative study. Arch Otolaryngol Head Neck Surg; 2006 Jan;132(1):73-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Craniofacial resection for malignant melanoma of the skull base: report of an international collaborative study.
  • OBJECTIVE: To report postoperative mortality, complications, and outcomes in a subset of patients with the histologic diagnosis of malignant melanoma extracted from an existing database of a large cohort of patients accumulated from multiple institutions.
  • SETTING: Seventeen international tertiary referral centers performing craniofacial surgery for malignant skull base tumors.
  • PATIENTS: A total of 53 patients were identified from a database of 1307 patients who had craniofacial resection for malignant tumors at 17 institutions.
  • Of the 53 patients, 25 (47%) had had prior single modality or combined treatment, which included surgery in 22 (42%), radiation in 11 (21%), and chemotherapy in 2 (4%).
  • Adjuvant radiotherapy was given in 22 (42%), chemotherapy in 3 (6%), and vaccine or interferon therapy in 2 (4%).
  • The extent of orbital involvement and adjuvant postoperative radiation therapy (PORT) were independent predictors of DSS and OS on multivariate analysis, whereas only PORT was an independent predictor of RFS.
  • CONCLUSIONS: Craniofacial resection in patients with malignant melanoma of the skull base has mortality (6%) and complication rates (26%) comparable to other malignant tumors of the skull base.
  • However, malignant melanoma is associated with a much poorer OS, DSS, and RFS.
  • These factors must be taken into account when considering craniofacial resection in a patient with malignant melanoma invading the skull base.
  • [MeSH-major] Cranial Fossa, Anterior / surgery. Facial Bones / surgery. Melanoma / surgery. Skull Base Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16415433.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Aida K, Monia K, Ahlem S, Dominique HT, Becima F, Sylvie F, Ridha KM: Agminated Spitz nevi arising on a nevus spilus after chemotherapy. Pediatr Dermatol; 2010 Jul-Aug;27(4):411-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Agminated Spitz nevi arising on a nevus spilus after chemotherapy.
  • We report here a further case in a child that is original because it is induced by chemotherapy.
  • A 3-year-old boy presented 3 months after the onset of a chemotherapy for a vesico-prostatic rhabdomyosarcoma, multiple pigmented papulo-nodules located on the face, neck, chest wall, and the higher back.
  • These lesions have arose on a pre-existent large congenital histologically confirmed nevus spilus extending along the face, neck, the left shoulder and the left chest wall.
  • Histological examination of three excised nodules led to the diagnosis of Spitz nevus.
  • Our patient may have a high risk for melanoma since he has many criteria predisposing to this risk.
  • Some of these criteria are related to NS but we should also take into account the chemotherapy induction and the high number of Spitz nevi.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Nevus, Epithelioid and Spindle Cell / chemically induced. Prostatic Neoplasms / drug therapy. Rhabdomyosarcoma / drug therapy. Skin Neoplasms / chemically induced. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Child, Preschool. Face. Humans. Male. Neck. Shoulder. Thoracic Wall


30. Leach BC, Kulbersh JS, Day TA, Cook J: Cranial neuropathy as a presenting sign of recurrent aggressive skin cancer. Dermatol Surg; 2008 Apr;34(4):483-97
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cranial neuropathy as a presenting sign of recurrent aggressive skin cancer.
  • OBJECTIVE: The purpose of this study was to identify and characterize recurrent skin cancers of the head and neck presenting with cranial neuropathies and to review the presentation and the management for this rare subset of cutaneous neoplasms.
  • MATERIALS AND METHODS: A retrospective review was performed for all patients with previous related cutaneous neoplasms presenting with cranial neuropathies referred to a single academic tertiary-care head and neck tumor program from 1999 to 2007.
  • Six cases of head and neck carcinoma with demonstrable cranial neuropathy were identified and analyzed by clinical history, radiographic and surgical findings, and treatment and survival data.
  • A review of the literature, pertinent anatomy, imaging studies, and surgical/nonsurgical management are summarized for these aggressive neurotropic malignancies.
  • The tumors involved were squamous cell carcinoma (4) and melanoma (2).
  • Symptoms were present for an average of 7 months prior to diagnosis of perineural recurrence.
  • Cranial nerve involvement was confirmed in all patients by magnetic resonance imaging, and five patients manifested histologic evidence of perineural tumor infiltration.
  • Treatment consisted of various combinations of surgery, radiation, and chemotherapy for five patients, and one patient declined any intervention.
  • CONCLUSION: Cranial neuropathy is a rare presentation of recurrent cutaneous neoplasms of the head and neck.
  • Given this infrequent occurrence and shared features of presentation, these highly morbid tumors are often mistakenly diagnosed as Bell's palsy or trigeminal neuralgia.
  • Our findings corroborate previous reports of diagnostic delay, increased tumor burden, and worsened morbidity and mortality associated with such cutaneous malignancies.
  • The critical utility of radiologic imaging for staging and tumor delineation are also supported by our institutional data.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Cranial Nerve Diseases / etiology. Head and Neck Neoplasms / pathology. Melanoma / pathology. Neoplasm Recurrence, Local / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18248467.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Bütter A, Hui T, Chapdelaine J, Beaunoyer M, Flageole H, Bouchard S: Melanoma in children and the use of sentinel lymph node biopsy. J Pediatr Surg; 2005 May;40(5):797-800
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma in children and the use of sentinel lymph node biopsy.
  • BACKGROUND: The rarity of pediatric melanoma prompted our review of sentinel lymph node biopsy (SLNB) and associated prognosis.
  • METHODS: A chart review from 1989 to 2004 revealed 12 cases of cutaneous melanoma.
  • Variables analyzed included demographics, site, histology, tumor characteristics, nodal status, and distant metastasis (TMN status), SLNB and/or therapeutic lymph node dissection (TLND), adjuvant treatment, disease-free survival, and overall survival.
  • RESULTS: Mean age at diagnosis was 8.5 years with 7 of 12 patients younger than 10 years (range, 0.3-17.9 years).
  • Site distribution was the extremity (7), trunk (4), and head and neck (1).
  • All patients had wide local excision and primary closure or skin graft.
  • Only patients diagnosed after 2000 with melanomas thicker than 1 mm were offered SLNB (extremity = 2, trunk = 1, head and neck = 1).
  • Disease-free survival and overall survival by stage were stage I (n = 2, 3.9 years, 100%), stage II (n = 6, 7.7 years, 83%), stage III (n = 4, 2.6 years, 75%), and stage IV (n = 0).
  • A stage II patient with negative SLNB, adjuvant chemotherapy, and interferon died 26 months after diagnosis, and a stage III patient with clinically and pathologically positive nodes after TLND died 15 months after diagnosis.
  • CONCLUSION: Although a negative SLNB does not guarantee a favorable prognosis, its increasing use will further define its role in pediatric melanoma.
  • [MeSH-major] Lymphatic Metastasis / diagnosis. Melanoma / secondary. Sentinel Lymph Node Biopsy. Skin Neoplasms / surgery
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Female. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / surgery. Humans. Infant. Interferons / therapeutic use. Lymph Node Excision. Male. Prognosis. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15937817.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 9008-11-1 / Interferons
  •  go-up   go-down


32. Hu W, Nelson JE, Mohney CA, Willen MD: Malignant melanoma arising in a pregnant African American woman with a congenital blue nevus. Dermatol Surg; 2004 Dec;30(12 Pt 2):1530-2
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma arising in a pregnant African American woman with a congenital blue nevus.
  • BACKGROUND: The incidence of cutaneous melanoma in African-Americans is relatively low.
  • Despite the slightly greater occurrence of congenital melanocytic nevi in black persons compared with white persons, the cumulative risk of melanoma arising in these lesions is very small.
  • In addition, the overwhelming majority of melanomas in black persons occur on nonglaborous skin where congenital melanocytic nevi are rare.
  • OBJECTIVE: The objective was to describe and an unusual case of melanoma arising in a congenital nevus with combined features of a blue nevus on the scalp of a pregnant African-American woman.
  • RESULTS: Histologic examination revealed a polypoid malignant melanoma arising in association with a congenital blue nevus in a young African-American woman.
  • Pathology from parotidectomy and neck dissection confirmed metastatic melanoma involving two intraparotid lymph nodes and 3 of 26 cervical lymph nodes.
  • Despite aggressive chemotherapy, she died in 1 year after the diagnosis.
  • [MeSH-major] Melanoma / diagnosis. Nevus, Blue / congenital. Pregnancy Complications, Neoplastic / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Fatal Outcome. Female. Humans. Pregnancy. Scalp

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15606833.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Myers M, Gurwood AS: Periocular malignancies and primary eye care. Optometry; 2001 Nov;72(11):705-12
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In 1985, an estimated 92,000 new cases of skin malignancies were diagnosed worldwide.
  • Based on reports from the United States Environmental Protection Agency, as the stratospheric ozone layer continues to be depleted, the number of new cases of skin cancer are predicted to climb by as many as 12 million over the next 50 years.
  • Up to 90% of all cases of skin cancer occur in the vicinity of the head or neck and 10% of those involve the eyelids.
  • METHODS: We surveyed the literature regarding the incidence, diagnosis, differential diagnosis, management, prognosis, and prevention of the most common periocular malignancies.
  • The types of malignancies include basal cell carcinoma, squamous cell carcinoma, sebaceous cell carcinoma, and malignant melanoma.
  • RESULTS: The period of greatest risk for the development of skin cancer begins in the fourth decade and increases with advancing age.
  • Up to 20% of periocular skin lesions are malignant.
  • Perhaps the most-significant risk factor is innate skin coloration.
  • Workup for these entities includes biopsy as the first step in diagnosis and management of skin cancers.
  • Treatment alternatives, used when surgical intervention is unable to be tolerated, include radiation therapy, cryotherapy, chemotherapy, interferons, and recently developed photodynamic therapy.
  • CONCLUSION: The importance of gross observation, examination, and careful slit-lamp biomicroscopy of the ocular adnexa cannot be overstated as a means of detection, diagnosis, and management of beginning, impending, or worsening malignancies.
  • [MeSH-major] Eye Neoplasms / diagnosis. Primary Health Care / methods
  • [MeSH-minor] Diagnosis, Differential. Humans. Incidence. Prognosis. United States

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12363258.001).
  • [ISSN] 1529-1839
  • [Journal-full-title] Optometry (St. Louis, Mo.)
  • [ISO-abbreviation] Optometry
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 22
  •  go-up   go-down


34. Gökmen Soysal H, Ardiç F: Malignant conjunctival tumors invading the orbit. Ophthalmologica; 2008;222(5):338-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant conjunctival tumors invading the orbit.
  • AIM: The aim of this study is to present the clinical and histopathological features as well as the treatment results of advanced conjunctival malignant tumors with orbital invasion, in the context of all secondary orbital tumors.
  • The age, gender, duration of symptoms, clinical and histopathological features and the treatment results of patients were recorded.
  • RESULTS: Four out of 21 patients had malignant melanoma (MM), while 17 had squamous cell carcinoma (SCC) of the conjunctiva.
  • Two patients underwent wide excision with control of the surgical margins and postoperative adjunctive topical chemotherapy.
  • Two patients with regional metastasis were treated by radical neck dissection and radiation therapy to the neck.
  • After a mean follow-up time of 35.6 months, no tumor recurrence or tumor-related death was encountered.
  • Seven patients died from non-tumor-related causes.
  • CONCLUSION: Delay in presentation for treatment and previous unsuccessful surgery of conjunctival malignant lesions are likely to lead to orbital invasion and loss of the eye.
  • Exenteration is generally needed but margin-controlled wide surgical excision and adjuvant chemotherapy may be curative in selected cases.
  • Early diagnosis and effective treatment of lesions will minimize the mortality rate and morbidity related to the disease.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Conjunctival Neoplasms / pathology. Melanoma / pathology. Orbital Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18635931.001).
  • [ISSN] 1423-0267
  • [Journal-full-title] Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift für Augenheilkunde
  • [ISO-abbreviation] Ophthalmologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


35. Terada T, Saeki N, Toh K, Uwa N, Sagawa K, Mouri T, Sakagami M: Primary malignant melanoma of the larynx: a case report and literature review. Auris Nasus Larynx; 2007 Mar;34(1):105-10
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant melanoma of the larynx: a case report and literature review.
  • A 56-year-old Japanese man presented with hoarseness and left sided neck swelling in June 2003.
  • Endoscopy showed an irregular tumor extending from the anterior commissure to the left ventricle with dark pigmentation.
  • A biopsy showed malignant melanoma.
  • A total laryngectomy with left radical neck dissection was performed in July 2003, followed by chemohormonal therapy and radiotherapy to the neck.
  • Multiple bone metastases were diagnosed in May 2004, and the patient died with disseminated disease in April 2005, 21 months after initial treatment.
  • The medical literature on laryngeal malignant melanoma was reviewed, and suggested a very poor prognosis despite therapy with surgery, radiotherapy, and chemotherapy.
  • [MeSH-major] Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / therapy. Melanoma / pathology. Melanoma / therapy
  • [MeSH-minor] Biopsy, Fine-Needle. Combined Modality Therapy. Fatal Outcome. Humans. Laryngeal Mucosa / pathology. Male. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17194557.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 43
  •  go-up   go-down


36. Little JW: Melanoma: etiology, treatment, and dental implications. Gen Dent; 2006 Jan-Feb;54(1):61-66; quiz, 67
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma: etiology, treatment, and dental implications.
  • Melanoma is one of the most serious skin cancers.
  • It arises from neural crest-derived melanocytes located in the epidermis or dermis of the skin.
  • Melanoma also can arise from melanocytes located in other regions of the body such as the eye, meninges, digestive tract, mucosal surfaces, or lymph nodes.
  • There are no proven causes of melanoma but the most commonly associated factor is episodic exposure to the sun.
  • Melanoma is a common cancer that has been increasing in incidence for the last 35 years.
  • The median age at the time of diagnosis is 53 years.
  • Five-year survival rates for melanoma of the skin have been increasing since 1976.
  • There are four types of melanoma: superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, and acral lintiginous melanoma.
  • Clinical signs indicating possible melanoma are asymmetry, border irregularity, color variation, increase in diameter, elevation, ulceration, and bleeding of pigmented lesions.
  • Histopathologic findings (tumor thickness, tumor invasion), surface ulceration, spread to lymph nodes, and distant metastases are used to project patient prognosis.
  • Treatment consists of surgical excision, lymph node dissection, limb perfusion, regional chemotherapy infusion, radiation, intralesional immunotherapy, systemic chemotherapy, and/or interferon-alpha, depending on the staging of the melanoma.
  • Oral melanomas are rare; however, approximately 20% of all melanomas are found in the head and neck region.
  • The role of the dentist is to be alert for changes in pigmented lesions of the oral mucosa and skin of the head and neck.
  • Lesions suspected of melanoma must be biopsied, which usually involves referral of the patient.
  • [MeSH-major] Head and Neck Neoplasms. Melanoma. Mouth Neoplasms / diagnosis
  • [MeSH-minor] Ethnic Groups. Humans. Neoplasm Staging. Prognosis. Sunlight / adverse effects. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16494125.001).
  • [ISSN] 0363-6771
  • [Journal-full-title] General dentistry
  • [ISO-abbreviation] Gen Dent
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 44
  •  go-up   go-down


37. Mücke T, Hölzle F, Kesting MR, Loeffelbein DJ, Robitzky LK, Hohlweg-Majert B, Tannapfel A, Wolff KD: Tumor size and depth in primary malignant melanoma in the oral cavity influences survival. J Oral Maxillofac Surg; 2009 Jul;67(7):1409-15
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor size and depth in primary malignant melanoma in the oral cavity influences survival.
  • PURPOSE: Primary oral malignant melanoma (OMM) is rare, and there are few studies examining the impact of this disease.
  • This study aims to assess the outcome of surgically treated patients with OMM treated at a single institution.
  • Treatment included wide local excision with or without modified neck dissection, supplemented by radiotherapy and chemotherapy.
  • RESULTS: Five patients were diagnosed with stage I disease, 4 with stage II disease, and 1 with stage III disease at presentation.
  • The adjusted hazard ratio was 4.513 (95% confidence interval, 1.47-13.89) for size and 1.919 (95% confidence interval, 1.03-3.59) for depth, yielding a poor prognosis (P = .009 and P = .048, respectively).
  • Early identification of OMM and its treatment by radical surgery comprise the single most important treatment strategy.
  • Any pigmented lesion in the oral cavity not clearly clinically amenable to diagnosis should be excised for histologic confirmation.
  • In cases in which the mucosal melanoma may not be the primary site, all potential primary sites should be examined.
  • [MeSH-major] Melanoma / mortality. Melanoma / pathology. Mouth Mucosa / pathology. Mouth Neoplasms / mortality. Mouth Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19531410.001).
  • [ISSN] 1531-5053
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Chiewvit P, Danchaivijitr N, Sirivitmaitrie K, Chiewvit S, Thephamongkhol K: Does magnetic resonance imaging give value-added than bone scintigraphy in the detection of vertebral metastasis? J Med Assoc Thai; 2009 Jun;92(6):818-29
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does magnetic resonance imaging give value-added than bone scintigraphy in the detection of vertebral metastasis?
  • OBJECTIVE: To determine the role of Magnetic Resonance (MR) imaging for the investigation ofpatients with suspected metastasis to the spine by bone scintigraphy.
  • MATERIAL AND METHOD: Retrospectively reviewed with comparison was made between Technetium-99m Methylene Diphosphonate (99(m)Tc-MDP) bone scintigraphy and corresponding spine MR images in 48 cases of vertebral metastasis at Siriraj Hospital.
  • The intervals between bone scintigraphy and MR images did not exceed 1 month.
  • The authors studied between January 2005 and December 2006 Bone scintigraphy were performed with planar imaging of the entire body and MR imaging was performed with the 1.5 tesla and 3.0 tesla scanner using standard techniques with T1-, T2-weighted images and fat-suppressed T1-weighted images with intravenous administration of gadopentetate dimeglumine.
  • The MR imaging findings were studied: location (cervical or thoracic or lumbar or sacrum spine), number of lesions (solitary or multiple lesions), pattern of enhancement (homogeneous or inhomogeneous), involvement of spinal canal, compression of spinal cord, extradural extension, other incidental findings such as pulmonary metastasis, pleural effusion, lymphadenopathy The final diagnosis was confirmed clinically and followed-up for further management (radiation or surgery) or followed-up by MR imaging (1 month-16 months) and bone scintigraphy (5 months-12 months).
  • Primary neoplasms include breast cancer (n=11), colorectal cancer (n=7), lung cancer (n=6), prostate cancer (n=5), nasopharyngeal cancer (n=5), head and neck cancer (n=3), thyroid cancer (n=2), liver cancer (n=2), esophagus cancer (n=1), bladder cancer (n=1), retroperitoneum cancer (n=1), medulloblastoma (n=1), cervical cancer (n=1), ovarian cancer (n=1), malignant melanoma (n=1).
  • The result of bone scintigraphy and MR imaging is used to evaluate vertebral metastasis: in 44 lesions of bone scintigraphy positive for vertebral metastasis, 40/44 lesions (91%) which MR imaging reveal vertebral metastasis.
  • This group may not benefit for further investigation by MR imaging.
  • Furthermore, MR imaging is important for the further treatment planning such as radiation therapy or systemic chemotherapy.
  • Although MR imaging is useful in the detection of early metastasis that are localized completely in the bone marrow cavity routinely bone scintigraphy remains that most cost-effective method for examination of the entire skeleton.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19530588.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Diphosphonates; 0 / Organotechnetium Compounds; 0 / technetium 99m methylene bisphosphonate
  •  go-up   go-down


39. Schreml S, Gantner S, Steinbauer J, Babilas P, Landthaler M, Szeimies RM: Melanoma promotion after photodynamic therapy of a suspected Bowen's disease lesion. Dermatology; 2009;219(3):279-81
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma promotion after photodynamic therapy of a suspected Bowen's disease lesion.
  • We report on a 61-year-old male patient who developed a melanoma at the site of a suspected Bowen's lesion on the right cheek.
  • This lesion had evolved for years and had been treated using photodynamic therapy (PDT) in an outpatient facility.
  • Only a couple of months after a single PDT treatment, a melanoma was histologically diagnosed.
  • The therapeutic strategy comprised re-excision, neck dissection and lateral parotidectomy - due to a metastasis - as well as subsequent alpha-interferon injections.
  • The possible role of PDT in the promotion of melanoma is discussed.
  • [MeSH-major] Bowen's Disease / drug therapy. Melanoma / etiology. Photochemotherapy / adverse effects. Photosensitizing Agents / adverse effects. Skin Neoplasms / drug therapy
  • [MeSH-minor] Biopsy. Cheek. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Bowen's Disease.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 S. Karger AG, Basel.
  • (PMID = 19729877.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Photosensitizing Agents
  •  go-up   go-down


40. Kung B, Aftab S, Wood M, Rosen D: Malignant melanoma metastatic to the thyroid gland: a case report and review of the literature. Ear Nose Throat J; 2009 Jan;88(1):E7
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma metastatic to the thyroid gland: a case report and review of the literature.
  • The thyroid gland is a relatively uncommon site for a secondary malignancy; even less common is a case of malignant melanoma metastatic to the thyroid.
  • We describe the case of a 68-year-old man who presented with a neck mass in the posterior triangle.
  • Fine-needle aspiration biopsy (FNAB) identified the mass as a malignant melanoma.
  • The patient had had no known primary skin melanoma.
  • He underwent a left modified radical neck dissection, and the mass was discovered to be a positive lymph node.
  • Postoperatively, he declined to undergo radio- and chemotherapy.
  • FNAB again attributed the enlargement to malignant melanoma.
  • Soon thereafter, the patient began experiencing seizures, and on magnetic resonance imaging, he was found to have metastatic disease to the brain.
  • He developed ventilator-dependent respiratory failure and required a subtotal thyroidectomy for the placement of a tracheostomy tube.
  • Patients who present with a thyroid nodule and who have a history of malignancy present a diagnostic dilemma: Is the nodule benign, a new primary, or a distant metastasis?
  • The findings of this case and a review of the literature strengthen the argument that any patient with a thyroid mass and a history of malignancy should be considered to have a metastasis until proven otherwise.
  • [MeSH-major] Melanoma / secondary. Neoplasm Invasiveness / pathology. Thyroid Neoplasms / secondary. Thyroid Nodule / pathology
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Follow-Up Studies. Humans. Immunohistochemistry. Lymph Nodes / pathology. Male. Neck Dissection. Neoplasm Staging. Risk Assessment. Thyroidectomy / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19172560.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


41. Bilaç C, Müezzinoğlu T, Ermertcan AT, Kayhan TC, Temeltaş G, Oztürkcan S, Temiz P: Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma. Cutan Ocul Toxicol; 2009;28(2):90-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sorafenib is a new therapeutic agent being used in metastatic renal cell carcinoma, hepatocellular carcinoma, and malignant melanoma.
  • The most frequently seen cutaneous side effects due to sorafenib are erythema, exfoliative dermatitis, acne vulgaris, and flushing.
  • On the third day of sorafenib therapy his lesions occurred.
  • His dermatologic examination revealed multiple erythematous papules on his neck, arms, and legs and bullae and iris lesions on his palms and soles.
  • He was diagnosed as having erythema multiforme.
  • We present this interesting case to show and discuss cutaneous side effects of sorafenib, especially erythema multiforme as a very rare cutaneous side effect.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Benzenesulfonates / adverse effects. Carcinoma, Renal Cell / drug therapy. Erythema Multiforme / chemically induced. Kidney Neoplasms / drug therapy. Pyridines / adverse effects
  • [MeSH-minor] Dose-Response Relationship, Drug. Humans. Male. Middle Aged. Niacinamide / analogs & derivatives. Phenylurea Compounds. Treatment Outcome

  • Genetic Alliance. consumer health - Erythema Multiforme.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19514932.001).
  • [ISSN] 1556-9535
  • [Journal-full-title] Cutaneous and ocular toxicology
  • [ISO-abbreviation] Cutan Ocul Toxicol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


42. Maheshwari V, Jindal A, Ashraf M, Sharma SC: Malignant melanoma of the nasal cavity. Indian J Otolaryngol Head Neck Surg; 2004 Jul;56(3):223-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma of the nasal cavity.
  • Malignant melanomas of the sinonasal mucosa are very uncommon, presenting frequently in advanced stages with usually a fatal course.
  • Diagnosis becomes more difficult if it is amelanotic variety.
  • Radical surgery is constrained because of increased morbidity & cosmesis, moreover radiotherapy and chemotherapy have little role if any to play.
  • A case of 60 years old male who presented with nasal mass and epistaxis finally diagnosed as melanoma on histolopathology.
  • Some other important aspects of this rare tumor are discussed here.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Otorhinolaryngol Ital. 2002 Aug;22(4):248-51 [12379047.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Feb;36(2):151-8 [12508243.001]
  • [Cites] Magn Reson Imaging Clin N Am. 2002 Aug;10(3):467-93 [12530230.001]
  • [Cites] Arch Pathol Lab Med. 2003 Aug;127(8):997-1002 [12873174.001]
  • [Cites] Am J Surg Pathol. 2003 May;27(5):594-611 [12717245.001]
  • (PMID = 23120081.001).
  • [ISSN] 2231-3796
  • [Journal-full-title] Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
  • [ISO-abbreviation] Indian J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3451887
  • [Keywords] NOTNLM ; Malignant Melanoma / nose / sinonasal mucosa
  •  go-up   go-down


43. Suzuki Y, Aoyama N, Minamide J, Takata K, Ogata T: Amelanotic malignant melanoma of the esophagus: report of a patient with recurrence successfully treated with chemoendocrine therapy. Int J Clin Oncol; 2005 Jun;10(3):204-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amelanotic malignant melanoma of the esophagus: report of a patient with recurrence successfully treated with chemoendocrine therapy.
  • We report a case of primary amelanotic malignant melanoma of the esophagus, an extremely rare disease.
  • A 58-year-old man was diagnosed as having middle esophageal cancer with lymph node metastasis, which was classified as esophageal cancer, Stage III:T3N1M0, by International Union Against Cancer (UICC) criteria.
  • Preoperative chemotherapy was performed, but the response assessment was no change (NC).
  • The patient underwent a subtotal esophagectomy via right thoracotomy and laparotomy.
  • Reconstruction was performed by pulling up the stomach via the retrosternal route; the site of anastomosis was the neck.
  • Adjuvant chemotherapy consisted of five courses of dacarbazine (DITC), nimustine (ACNU), vincristine (VCR), and interferon-beta.
  • Eleven months after the surgery, computed tomography (CT) demonstrated recurrence in the upper mediastinum.
  • The patient received chemoendocrine therapy, consisting of the first planned course of DITC, ACNU, and cisplatin (CDDP), given intravenously; and tamoxifen (TAM), given orally.
  • Subsequently with a modified regimen of this therapy he attained a complete response (CR).
  • In general, the prognosis of esophageal malignant melanoma is very poor.
  • Although our patient had a recurrence, he is alive 4 years and 5 months after the surgery and 3 years and 6 months after the recurrence.
  • The chemoendocrine therapy probably contributed to this outcome.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophageal Neoplasms / drug therapy. Melanoma / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Dacarbazine / administration & dosage. Esophagectomy. Humans. Infusions, Intravenous. Interferon-beta / administration & dosage. Male. Middle Aged. Nimustine / administration & dosage. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1990 Mar 7;82(5):361-70 [2406452.001]
  • [Cites] Gastroenterol Jpn. 1991 Apr;26(2):209-12 [2040402.001]
  • [Cites] Jpn J Clin Oncol. 1990 Sep;20(3):286-95 [2255105.001]
  • [Cites] Thorax. 1991 May;46(5):397-8 [2068703.001]
  • [Cites] Jpn J Clin Oncol. 1998 Dec;28(12):758-61 [9879295.001]
  • [Cites] Eur J Cancer Clin Oncol. 1984 Jul;20(7):983-5 [6611266.001]
  • [Cites] J Immunol. 1983 Dec;131(6):2767-71 [6605988.001]
  • [Cites] Surg Today. 1993;23(9):820-4 [8219617.001]
  • [Cites] Trop Gastroenterol. 2000 Oct-Dec;21(4):185-7 [11194582.001]
  • [Cites] N Engl J Med. 1979 Nov 29;301(22):1241-2 [503125.001]
  • [Cites] Yonsei Med J. 1998 Oct;39(5):468-73 [9821797.001]
  • [Cites] N Engl J Med. 1992 Aug 20;327(8):516-23 [1635566.001]
  • [Cites] Dis Esophagus. 2000;13(4):320-3 [11284983.001]
  • [Cites] Cancer Treat Rep. 1984 Nov;68(11):1403-5 [6541973.001]
  • [Cites] Cancer. 1989 Apr 1;63(7):1292-5 [2920358.001]
  • (PMID = 15990972.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0S726V972K / Nimustine; 5J49Q6B70F / Vincristine; 77238-31-4 / Interferon-beta; 7GR28W0FJI / Dacarbazine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


44. Powell AM, Robson AM, Russell-Jones R, Barlow RJ: Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with long-term follow-up. Br J Dermatol; 2009 May;160(5):994-8
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with long-term follow-up.
  • BACKGROUND: Melanoma in situ/lentigo maligna (LM) is a potential precursor of LM melanoma.
  • It occurs most commonly in elderly individuals on sun-exposed skin of the head and neck.
  • Although surgical excision is the treatment of choice, this may not be desirable or feasible for large lesions at functionally or cosmetically important sites.
  • Pretreatment diagnostic biopsies were also reviewed and histologically graded.
  • There were 37 responders and 11 treatment failures (of whom two were 'partial responders').
  • One patient in whom treatment failed subsequently developed invasive disease.
  • We could not identify histological features of prognostic significance.
  • However, the ability to develop an inflammatory reaction to imiquimod was a strong predictor of therapeutic benefit.
  • CONCLUSIONS: We consider imiquimod to have a role in the treatment of LM in patients in whom surgery may be contraindicated or for those in whom the cosmetic or functional consequences may be considerable.
  • Until better characterized, its use should probably be confined to centres with experience in the detection and treatment of LM and melanoma.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Facial Neoplasms / drug therapy. Hutchinson's Melanotic Freckle / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Adult. Aged. Aged, 80 and over. Biopsy. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19222462.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


45. Murakami M, Wada T, Kashiwagi T, Ishida-Yamamoto A, Iizuka H: Nodular malignant melanoma with Spitz nevus-like pathological features finally confirmed by the pathological feature of the sentinel lymph node. J Dermatol; 2007 Dec;34(12):821-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular malignant melanoma with Spitz nevus-like pathological features finally confirmed by the pathological feature of the sentinel lymph node.
  • The clinical and histopathological similarities of nodular melanoma and Spitz nevus currently still make a definitive diagnosis difficult.
  • We report here a case of nodular melanoma that was extremely difficult to diagnose both clinically and histopathologically.
  • The primary tumor was a blackish nodule on the scalp and biopsy was performed for pathological diagnosis.
  • Although our first impression was malignant melanoma, we asked two dermatopathologists for second opinions; however, one diagnosed a melanoma and the other a Spitz nevus.
  • Histopathological diagnosis to establish whether it was a melanoma metastasis or nodal nevi was also difficult, and we again asked for second opinions from another dermatopathologist in the USA.
  • According to its clinical course and the histopathology of the sentinel lymph node with additional immunohistochemistry, this case was finally diagnosed as a nodular melanoma (T4aN1aM0, stage IIIA).
  • To date, the patient has been given five courses of chemotherapy at 6-month intervals, with no local recurrence or distant metastases so far.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Melanoma / pathology. Scalp. Skin Neoplasms / pathology


46. Lang PG: Current concepts in the management of patients with melanoma. Am J Clin Dermatol; 2002;3(6):401-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current concepts in the management of patients with melanoma.
  • Melanoma is a significant health problem.
  • Despite public education and free cancer screenings, the incidence and mortality of melanoma continues to rise; however, many currently diagnosed melanomas are thin lesions, suggesting that education and awareness is having an impact.
  • Although large congenital nevi may be precursors of melanoma, small and medium congenital nevi have an insignificant risk for melanoma development.
  • Large congenital nevi, which are axial in location, appear to be more likely to develop melanoma and are associated with melanocytosis and melanoma of the CNS, both of which portend a poor prognosis.
  • Recently, the recommended margins of excision have become more conservative so that many of the surgical defects can be closed primarily.
  • Lymphoscintigraphy and sentinel node biopsy have replaced elective node dissections, thus decreasing the morbidity associated with the surgical management of melanoma.
  • Although controversy still exists as to whether or not sentinel lymph node biopsy alters a patient's prognosis, it has been shown to be a powerful prognostic indicator.
  • Although most melanomas are managed by routine surgical excision, other modalities are sometimes employed.
  • For example, cryosurgery or radiation therapy may be indicated in the frail, elderly individual with a large facial lentigo maligna.
  • Mohs surgery is the treatment of choice for head and neck melanomas and those located in areas where maximum preservation of tissue is required and for desmoplastic and acral lentiginous melanomas.
  • Much more work remains in the area of adjuvant therapy, chemotherapy, and immunotherapy.
  • Dacarbazine remains the drug of choice in disseminated melanoma, but remissions are usually short lived.
  • Although high dose interferon increases disease-free and overall survival in some patients, it remains a controversial drug which is not easily tolerated.
  • In the new staging system for melanoma, ulceration is second only to Breslow's thickness.
  • The new system also recognizes that patients with only microscopic metastatic nodal disease fare better than patients with clinically enlarged metastatic nodes and that it is the number of nodes involved with metastases, not their size, that determines the patient's prognosis.
  • Except for lesions <1mm thick, the Clark's level of invasion has been de-emphasized.
  • [MeSH-major] Melanoma. Skin Neoplasms
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Female. Humans. Incidence. Interferon-alpha / therapeutic use. Lymph Node Excision. Male. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neoplasm Staging. Pregnancy. Pregnancy Complications, Neoplastic / diagnosis. Pregnancy Complications, Neoplastic / therapy. Prognosis. Recombinant Proteins. Risk Factors

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12113649.001).
  • [ISSN] 1175-0561
  • [Journal-full-title] American journal of clinical dermatology
  • [ISO-abbreviation] Am J Clin Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  • [Number-of-references] 285
  •  go-up   go-down


47. Prayson RA, Sebek BA: Parotid gland malignant melanomas. Arch Pathol Lab Med; 2000 Dec;124(12):1780-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parotid gland malignant melanomas.
  • BACKGROUND: Malignant melanomas are relatively unusual tumors in the parotid gland.
  • The majority of previously reported cases appear to represent metastatic lesions, often from cutaneous head and neck primaries.
  • METHODS: Retrospective clinicopathologic review of 12 cases of malignant melanoma involving the parotid gland encountered between 1980 and October 1999 at a tertiary referral center.
  • Eleven of 12 patients presented with a neck mass or nodule.
  • In 9 of 12 patients, a cutaneous or conjunctival primary was noted in the head region.
  • In 2 patients, a cutaneous melanoma and the parotid gland melanoma were diagnosed at the same time.
  • In 1 patient, melanoma was initially diagnosed in the parotid gland, and a definite primary was not uncovered.
  • All patients underwent excision of the parotid melanoma, which was accompanied by a lymph node biopsy or dissection in 10 out of 11 patients.
  • Four patients received adjuvant radiotherapy, and 3 patients received adjuvant chemotherapy.
  • Four of 11 patients had ipsilateral cervical lymph node metastasis at the time of parotid tumor resection, and 5 patients had involvement of intraparotid lymph nodes by metastatic melanoma.
  • Intravascular and/or lymphatic involvement by tumor within the parotid gland was noted in 3 lesions.
  • At last known follow-up, 6 patients had died with tumor at a median follow-up period of 11 months after parotid gland surgery.
  • Four patients were alive with evidence of tumor at follow-up intervals of 4, 17, 21, and 113 months after parotid gland surgery.
  • Two patients were alive with no evidence of residual tumor at 20 and 148 months of follow-up.
  • CONCLUSIONS: The majority of melanomas involving the parotid gland appeared to be associated with lymph node metastasis in and around the gland from a cutaneous primary in the head region.
  • Prognosis is generally poor, although rare patients may survive a long period of time following surgery.
  • [MeSH-major] Melanoma / pathology. Parotid Neoplasms / secondary. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11100057.001).
  • [ISSN] 0003-9985
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


48. Khoury-Helou A, Lozac'h C, Vandenbrouke F, Lozac'h P: [Primary malignant melanoma of the esophagus]. Ann Chir; 2001 Jul;126(6):557-60
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary malignant melanoma of the esophagus].
  • [Transliterated title] Le mélanome malin primitif de l'oesophage.
  • The primary malignant melanoma of the esophagus is a rare tumor.
  • The study aim was to report two cases, one treated by esophagectomy without thoracotomy and the other one by Lewis-Santy type esophagectomy.
  • The other one who had a cervical invaded lymph node, treated by radio-chemotherapy, is actually in complete remission 9 years after the diagnosis.
  • [MeSH-major] Esophageal Neoplasms / surgery. Esophagectomy / methods. Melanoma / surgery
  • [MeSH-minor] Aged. Combined Modality Therapy. Fatal Outcome. Humans. Male. Neoplasm Metastasis. Neoplasm Recurrence, Local. Thoracotomy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11486540.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


49. Manouras A, Lagoudianakis EE, Genetzakis M, Pararas N, Papadima A, Kekis PB: Metastatic breast carcinoma initially presenting as acute cholecystitis: a case report and review of the literature. Eur J Gynaecol Oncol; 2008;29(2):179-81
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: The gallbladder is an infrequent site of metastatic malignant disease.
  • Although malignant melanoma, renal cell and cervical carcinoma have been documented, breast carcinoma has rarely been reported to metastasize in the gallbladder.
  • CASE REPORT: We describe such a case that manifested as acute cholecystitis and was incidentally recognized after cholecystectomy, in an otherwise disease-free 46-year-old female who had undergone mastectomy for breast cancer two years before.
  • The patient was subjected to adjuvant chemotherapy, but unfortunately died just a year after diagnosis because of generalized peritoneal seeding of the tumor.
  • DISCUSSION: Metastatic gallbladder involvement is rare, especially in cases of primary breast carcinoma, usually leading to symptoms of abdominal pain, mimicking acute or chronic cholecystitis.
  • Thus, abdominal pain in a patient with a previous history of breast carcinoma should raise suspicion of gallbladder metastasis.

  • Genetic Alliance. consumer health - Cholecystitis.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18459559.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


50. Lin CY, Yang SW, Lai CH: Primary malignant melanoma of the nasal cavity. Chang Gung Med J; 2003 Nov;26(11):857-62
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant melanoma of the nasal cavity.
  • Malignant melanoma is a highly lethal melanocytic neoplasm, usually affecting the skin.
  • Primary malignant melanoma of the nasal cavity is rarely seen.
  • The prognosis is generally poor, with a mean survival time of 3.5 years.
  • The usual treatment of choice is radical excision.
  • Radiotherapy and chemotherapy appear to have little effect.
  • We report a fatal case of intranasal cavity malignant melanoma in which the patient initially presented with blood-tinged sputum, productive cough, and intermittent fever.
  • Palliative surgery was performed to excise the nasal cavity tumor.
  • Then, 6 courses of chemotherapy were further administered.
  • Unfortunately, regional cervical nodal involvement and pancreatic head metastases occurred 1.5 years after the diagnosis.
  • The patient's condition rapidly deteriorated, followed by death.
  • We have chosen to discuss this aggressive condition because of its rarity and also to emphasize the importance of its early detection through vigilant attention to nonspecific nasal symptoms.
  • A review of the literature concerning intranasal malignant melanoma is presented.
  • We further discuss its possible etiology, site of origin, incidence, clinical presentations, principles of management, and outcome.
  • [MeSH-major] Melanoma / pathology. Nasal Cavity. Nose Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14765758.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


51. Jacob A, Brightman RP, Welling DB: Bilateral cerebellopontine angle metastatic melanoma: a case report. Ear Nose Throat J; 2007 Jul;86(7):388-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral cerebellopontine angle metastatic melanoma: a case report.
  • Although melanoma accounts for approximately 1% of all malignancies, melanoma metastases to the cerebellopontine angles (CPAs) are exceedingly rare.
  • Here we describe a patient with melanoma metastases to the internal auditory canals and CPAs who presented with a remote history of cutaneous melanoma.
  • This patient had a rapidly progressive hearing loss, vestibulopathy, and facial nerve dysfunction.
  • The diagnosis required a careful history, unilateral surgical resection for tissue acquisition, and histopathologic confirmation.
  • A search for primary cutaneous melanoma at the time of presentation was negative.
  • However, the history of cutaneous melanoma 8 years earlier distinguishes this patient's metastatic disease from solitary primary intracranial melanoma, an equally rare disease.
  • Treatment consists of surgical excision, radiation, chemotherapy, and immunotherapy.
  • The prognosis for patients with melanoma metastases is generally poor, but isolated reports of long-term survival have been described.
  • Metastatic disease to the CPAs must be included in the differential diagnosis for any patient presenting with rapid-onset VIIth or VIIIth cranial nerve symptoms.
  • [MeSH-major] Cerebellar Neoplasms / secondary. Cerebellopontine Angle. Melanoma / secondary. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17702316.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Dal Maso L, Polesel J, Serraino D, Lise M, Piselli P, Falcini F, Russo A, Intrieri T, Vercelli M, Zambon P, Tagliabue G, Zanetti R, Federico M, Limina RM, Mangone L, De Lisi V, Stracci F, Ferretti S, Piffer S, Budroni M, Donato A, Giacomin A, Bellù F, Fusco M, Madeddu A, Vitarelli S, Tessandori R, Tumino R, Suligoi B, Franceschi S, Cancer and AIDS Registries Linkage (CARL) Study: Pattern of cancer risk in persons with AIDS in Italy in the HAART era. Br J Cancer; 2009 Mar 10;100(5):840-7
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pattern of cancer risk in persons with AIDS in Italy in the HAART era.
  • A record-linkage study was carried out between the Italian AIDS Registry and 24 Italian cancer registries to compare cancer excess among persons with HIV/AIDS (PWHA) before and after the introduction of highly active antiretroviral therapy (HAART) in 1996.
  • SIR for Kaposi sarcoma (KS) and non-Hodgkin lymphoma greatly decreased in 1997-2004 compared with 1986-1996, but high SIRs for KS persisted in the increasingly large fraction of PWHA who had an interval of <1 year between first HIV-positive test and AIDS diagnosis.
  • A significant excess of liver cancer (SIR=6.4) emerged in 1997-2004, whereas the SIRs for cancer of the cervix (41.5), anus (44.0), lung (4.1), brain (3.2), skin (non-melanoma, 1.8), Hodgkin lymphoma (20.7), myeloma (3.9), and non-AIDS-defining cancers (2.2) were similarly elevated in the two periods.
  • The excess of some potentially preventable cancers in PWHA suggests that HAART use must be accompanied by cancer-prevention strategies, notably antismoking and cervical cancer screening programmes.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / drug therapy. Acquired Immunodeficiency Syndrome / epidemiology. Antiretroviral Therapy, Highly Active. Neoplasms / epidemiology. Neoplasms / etiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2003 Jul 7;89(1):94-100 [12838307.001]
  • [Cites] Lancet. 2009 Jan 10;373(9658):181-3 [18684500.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Apr 1;26(4):377-80 [11317082.001]
  • [Cites] AIDS. 2002 May 24;16(8):1155-61 [12004274.001]
  • [Cites] J Biomed Inform. 2001 Dec;34(6):387-95 [12198758.001]
  • [Cites] Lancet Oncol. 2003 Feb;4(2):110-9 [12573353.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Sep 1;34(1):84-90 [14501799.001]
  • [Cites] Antivir Ther. 2004 Feb;9(1):13-22 [15040532.001]
  • [Cites] AIDS. 2004 Jan 2;18(1):109-13 [15090836.001]
  • [Cites] J Natl Cancer Inst. 2004 Jul 21;96(14):1070-6 [15265968.001]
  • [Cites] IARC Sci Publ. 1987;(82):1-406 [3329634.001]
  • [Cites] Lancet. 1993 Feb 13;341(8842):441 [8094208.001]
  • [Cites] Br J Cancer. 1998 Oct;78(7):966-70 [9764592.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):467-75 [15734974.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] Clin Infect Dis. 2005 Jul 1;41(1):124-6; author reply 126-7 [15937776.001]
  • [Cites] AIDS Care. 2006 May;18(4):376-8 [16809116.001]
  • [Cites] Epidemiol Prev. 2006 Jan-Feb;30(1 Suppl 2):8-10, 12-28, 30-101 passim [16826725.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Arch Intern Med. 2006 Aug 14-28;166(15):1632-41 [16908797.001]
  • [Cites] Eur J Cancer Prev. 2006 Dec;15(6):554-6 [17106339.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Eur J Cancer. 2007 Apr;43(6):1085-91 [17349785.001]
  • [Cites] Am J Epidemiol. 2007 May 15;165(10):1143-53 [17344204.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Clin Infect Dis. 2007 Aug 15;45(4):510-3 [17638204.001]
  • [Cites] Eur J Cancer. 2007 Sep;43(14):2117-23 [17764927.001]
  • [Cites] AIDS. 2008 Jan 11;22(2):301-6 [18097233.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 2007;90:1-636 [18354839.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] Br J Cancer. 2008 Sep 2;99(5):800-4 [18665172.001]
  • [Cites] AIDS. 2008 Oct 18;22(16):2135-41 [18832877.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Nov 1;49(3):282-6 [18845959.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):505-7 [12888821.001]
  • (PMID = 19223894.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2653754
  • [Investigator] Zucchetto A; De Paoli A; Colamartini A; Autelitano M; Crocetti E; Marani E; Fiore AR; Tittarelli A; Rosso S; Rashid I; Donato F; Pezzarossi A; Sgargi P; La Rosa F; Franchini S; Zanier L; Cesaraccio R; Senatore G; Vercellino PC; Vittadello F; Contrino ML; Antonini S; Maspero S; La Rosa MG; Boros S; Salfa MC
  •  go-up   go-down


53. Vecil GG, Papadopoulos NV, Vassilopoulou-Sellin R, McCutcheon IE: Interferon-induced hypothyroidism causing reversible pituitary enlargement. Endocr Pract; 2008 Mar;14(2):219-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We describe the case of a woman with recurrent malignant melanoma, outline the details of her endocrine work-up, and illustrate the serial findings on magnetic resonance imaging of the head.
  • RESULTS: A 26-year-old woman underwent surgical excision of a melanoma of the left thigh and 10 years later had a second melanoma removed from her right knee.
  • Metastatic work-up revealed evidence of tumor involvement in the cervical and mediastinal lymph nodes.
  • After treatment with interferon for 1 year, persistent fatigue and menstrual irregularities led to the laboratory diagnosis of hypothyroidism, and magnetic resonance imaging revealed pituitary enlargement.
  • Both her endocrinopathy and the pituitary hyperplasia resolved with discontinuation of the interferon treatment and with institution of thyroid replacement therapy.
  • CONCLUSION: Clinicians should be aware of the potential adverse effects of interferon therapy to avoid inappropriate diagnosis of a pituitary adenoma or metastatic lesion in patients with cancer who are treated with interferon.
  • [MeSH-major] Hypothyroidism / chemically induced. Interferons / adverse effects. Pituitary Gland / drug effects

  • MedlinePlus Health Information. consumer health - Hypothyroidism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18308662.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9008-11-1 / Interferons
  •  go-up   go-down


54. Wu GH, Chen FJ, Zeng ZY, Li H, Lin GW, Song M, Wei MW, Xu GP, Yang AK, Chen WK: [Treatment of second primary malignant tumor induced by radiotherapy]. Zhonghua Zhong Liu Za Zhi; 2003 May;25(3):275-7
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of second primary malignant tumor induced by radiotherapy].
  • OBJECTIVE: To study the diagnosis and treatment of a second primary malignant tumor induced by previous radiotherapy.
  • METHODS: From March 1970 to March 1997, 108 nasopharyngeal cancer (NPC) patients who developed a second primary malignant tumor induced by radiotherapy were treated.
  • There were squamous carcinoma 43 (39.8%), sarcoma 26 (24.1%), malignant fibrous histiocytoma 14 (13.0%), adenoid cystic carcinoma 12 (11.1%), thyroid papillary adenocarcinoma 8 (7.4%) and malignant melanoma 5 (4.6%).
  • Fifty patients underwent operation, 32 received radiotherapy, 18 received chemotherapy and 8 received operation combined with chemotherapy.
  • RESULTS: The 3- and 5-year tumor-free survival rates were 64.0% and 36.0% in the operation group.
  • CONCLUSION: Surgery, if not contra-indicated, is the first choice for the second primary malignant tumor induced by radiotherapy.
  • Aggressive treatment for these patients is, hence, indicated clinically.
  • [MeSH-major] Neoplasms, Radiation-Induced / therapy. Neoplasms, Second Primary / therapy. Radiotherapy / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12839694.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


55. Dillman RO, Nanci AA, Williams ST, Kim RB, Hafer RL, Coleman CL, Wang PC, Duma CM, Chen PV, Selvan SR, Cornforth AN, DePriest C: Durable complete response of refractory, progressing metastatic melanoma after treatment with a patient-specific vaccine. Cancer Biother Radiopharm; 2010 Oct;25(5):553-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Durable complete response of refractory, progressing metastatic melanoma after treatment with a patient-specific vaccine.
  • A patient with metastatic melanoma who experienced a durable complete response after treatment with a patient-specific vaccine has been described in this article.
  • This 59-year-old woman presented with cervical spine metastases and, within the year, had experienced local disease progression and, despite various therapies, metastases to the axilla, rectum, gall bladder, and multiple soft-tissue sites.
  • She had previously received radiation therapy, combination chemotherapy, interleukin-2 plus interferon biotherapy, and gamma knife radiosurgery, and undergone multiple surgical resections.
  • At the time vaccine therapy was initiated, she had multiple, new, measurable, soft-tissue metastases that were increasing in size.
  • She was treated with a vaccine consisting of autologous dendritic cells incubated with irradiated tumor cells from an autologous tumor cell line and suspended in granulocyte-macrophage colony stimulating factor (GM-CSF), with subcutaneous injections once a week for 3 weeks and monthly for 5 months.
  • There was evidence of disease regression by the completion of therapy.
  • A few months later a complete response was documented by radiologic scans, and subsequently reconfirmed at 6-month intervals.
  • This is the first time she has been in a complete remission since her initial diagnosis.
  • Patient-specific vaccines can sometimes induce durable complete regression of progressing soft-tissue melanoma metastases.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Disease Progression. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Metastasis. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20849310.001).
  • [ISSN] 1557-8852
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines
  •  go-up   go-down


56. Khakoo AY, Halushka MK, Rame JE, Rodriguez ER, Kasper EK, Judge DP: Reversible cardiomyopathy caused by administration of interferon alpha. Nat Clin Pract Cardiovasc Med; 2005 Jan;2(1):53-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: A 56-year-old man with normal cardiac function received treatment with interferon alpha-2b for malignant melanoma.
  • Eight months after the initiation of therapy he developed fatigue and dyspnea on exertion.
  • Echocardiography revealed severe, global left-ventricular dysfunction.
  • DIAGNOSIS: Interferon alpha-2b-induced cardiomyopathy.
  • [MeSH-minor] Follow-Up Studies. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / surgery. Heart Failure / chemically induced. Humans. Male. Melanoma / drug therapy. Melanoma / surgery. Middle Aged. Myocarditis / chemically induced. Recombinant Proteins. Skin Neoplasms / drug therapy. Skin Neoplasms / surgery. Ventricular Dysfunction, Left / chemically induced

  • Genetic Alliance. consumer health - Cardiomyopathy.
  • MedlinePlus Health Information. consumer health - Cardiomyopathy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16265343.001).
  • [ISSN] 1743-4297
  • [Journal-full-title] Nature clinical practice. Cardiovascular medicine
  • [ISO-abbreviation] Nat Clin Pract Cardiovasc Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


57. Toyoshima M, Okamura C, Niikura H, Ito K, Yaegashi N: Epithelioid leiomyosarcoma of the uterine cervix: a case report and review of the literature. Gynecol Oncol; 2005 Jun;97(3):957-60
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE: A 53-year-old Japanese woman was admitted to our university hospital due to massive vaginal bleeding from a cervical tumor.
  • Histological findings, including immunohistochemical study using desmin, SMA, cytokeratin, S-100, HMB-45, vimentin, melan-A, and CD68, led to a diagnosis of epithelioid leiomyosarcoma of the uterine cervix.
  • The patient underwent adjuvant chemotherapy and has been disease-free for over 20 months.
  • CONCLUSION: Immunohistochemical studies may be needed to differentiate among the alternative diagnoses of malignant melanoma, metastatic carcinoma, and epithelioid sarcoma.
  • [MeSH-major] Leiomyosarcoma / pathology. Uterine Cervical Neoplasms / pathology

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15890394.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 10
  •  go-up   go-down


58. Akçay MN: Metastatic disease in the breast. Breast; 2002 Dec;11(6):526-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Breast cancer is the commonest malignancy in women.
  • Metastatic disease of the breast is therefore often an unexpected diagnosis in a female patient presenting with a breast mass.
  • Of solid tumors at other sites, the most common cancers to metastasize to the breast are, in declining order of frequency, malignant melanoma, lymphoma, lung cancer, ovarian carcinoma, soft tissue sarcoma, and gastrointestinal and genitourinary tumors.
  • Besides these, metastases from osteosarcoma, thyroid neoplasms, and cervical, vaginal and endometrial carcinomas to the breast have been sporadically reported in the literature.
  • Lesions that metastasize to the breast may produce changes that look similar to those of primary breast cancer on mammography, but they are more likely to be multiple, are frequently bilateral, and form a nidus of tumor cells that are usually round with fairly well-defined margins.
  • Microcalcifications are not a distinguishing feature, and although their margins may be ill defined, spiculations are not commonly found.
  • Diagnosis is generally achieved by means of fine-needle aspiration cytology or open biopsy of the breast masses.
  • In recent reports, particular importance has been attached to the performance of fine-needle aspiration cytology diagnosis, to differentiate a metastasis from a second primary tumor, thus making it possible to avoid unnecessary mastectomy and ensure that appropriate chemotherapy and radiotherapy are implemented.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14965721.001).
  • [ISSN] 0960-9776
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


59. Thompson LD, Wieneke JA, Miettinen M: Sinonasal tract and nasopharyngeal melanomas: a clinicopathologic study of 115 cases with a proposed staging system. Am J Surg Pathol; 2003 May;27(5):594-611
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sinonasal tract and nasopharyngeal melanomas: a clinicopathologic study of 115 cases with a proposed staging system.
  • Primary sinonasal tract mucosal malignant melanomas are uncommon tumors that are frequently misclassified, resulting in inappropriate clinical management.
  • A total of 115 cases of sinonasal tract mucosal malignant melanoma included 59 females and 56 males, 13-93 years of age (mean 64.3 years).
  • Histologically, the tumors were composed of a variety of cell types (epithelioid, spindled, undifferentiated), frequently arranged in a peritheliomatous distribution (n = 39).
  • Immunohistochemical studies confirmed the diagnosis of sinonasal tract mucosal malignant melanomas with positive reactions for S-100 protein, tyrosinase, HMB-45, melan A, and microphthalmia transcription factor.
  • Sinonasal tract mucosal malignant melanomas need to be considered in the differential diagnosis of most sinonasal malignancies, particularly carcinoma, lymphoma, sarcoma, and olfactory neuroblastoma.
  • Surgery accompanied by radiation and/or chemotherapy was generally used.
  • The majority of patients developed a recurrence (n = 79), with 75 patients dying with disseminated disease (mean 2.3 years), whereas 40 patients are either alive or had died of unrelated causes (mean 13.9 years).
  • A TNM-type classification separated by anatomic site of involvement and metastatic disease is proposed to predict biologic behavior.
  • [MeSH-major] Melanoma / secondary. Nasopharyngeal Neoplasms / pathology. Nose Neoplasms / pathology. Paranasal Sinuses / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Male. Middle Aged. Nasal Mucosa. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Survival Rate

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12717245.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


60. Tatla T, Hungerford J, Plowman N, Ghufoor K, Keene M: Conjunctival melanoma: the role of conservative surgery and radiotherapy in regional metastatic disease. Laryngoscope; 2005 May;115(5):817-22
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conjunctival melanoma: the role of conservative surgery and radiotherapy in regional metastatic disease.
  • OBJECTIVE: To evaluate prognostic factors and determine the role of conservative surgery and radiotherapy in managing metastatic conjunctival malignant melanoma (MM) involving preauricular/submandibular lymph nodes.
  • METHOD: A retrospective analysis (1990-2003) of clinical and histopathologic data from 12 patients presenting with regional metastases after failed local treatment for conjunctival MM.
  • Patients received a common, multispecialty, conservative management approach: wide local excision, topical cryotherapy or radiotherapy to conjunctival MM (orbital exenteration for more advanced local disease), lumpectomy, and adjuvant "ring" radiotherapy of regional metastases, with chemotherapy for distant metastases.
  • RESULTS: Median age at primary diagnosis was 51 (range 28-86) years with equal sex predilection.
  • Epithelioid tumor cells were noted histologically in seven of eight specimens in which cell type could be determined.
  • Eight tumors metastasised to preauricular nodes, three to submandibular and one to both, with a median interval of 23 (range 12-108) months after primary diagnosis.
  • After conservative surgery and "ring irradiation," 7 of 12 patients remained free of regional nodal relapse at median interval of 16 (range 3-126) months.
  • Five patients developed regional nodal recurrence at median interval of 11 (range 6-13) months, 3 of whom were within radiotherapy portals.
  • Eight patients developed distant metastasis at median interval of 44 (range 22-138) months.
  • Eleven patients had tumor-related death.
  • The mean Kaplan-Meier adjusted survival time after primary diagnosis was 76 months with death ensuing postregional metastasis within a median 18 (range 4-127) months.
  • CONCLUSION: Locoregional metastasis after treatment for conjunctival MM is associated with a poor prognosis.
  • Both epithelioid tumor cells and PAM are associated with disseminating disease and poorer outcome.
  • [MeSH-major] Conjunctival Neoplasms / radiotherapy. Conjunctival Neoplasms / surgery. Melanoma / radiotherapy. Melanoma / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Cryotherapy / methods. Female. Humans. Lymph Nodes. Male. Middle Aged. Neoplasm Recurrence, Local. Ophthalmologic Surgical Procedures / methods. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15867646.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Nishiura Y, Sakamoto K, Mihoki T, Takane Y, Maeda A, Miyajima Y, Nakashima T: [Autologous tumor-specific immunotherapy for recurrent malignant melanoma of the nasal cavity]. Nihon Jibiinkoka Gakkai Kaiho; 2006 Nov;109(11):781-4
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Autologous tumor-specific immunotherapy for recurrent malignant melanoma of the nasal cavity].
  • Malignant melanoma usually occurs in tissues containing large numbers of melanocytes, such as the skin, mucosa and eye, and is one of the most highly malignant tumors known.
  • No satisfactory treatment results have ever been reported.
  • We report here an effective course of immunotherapy consisting of the local injection and intra-venous administration of autologous tumor-cell-stimulated cytotoxic T lymphocytes in a patient with recurrent malignant melanoma.
  • The patient was a 45-year-old woman.
  • She had been diagnosed as having malignant melanoma in 1996 and under went radio-chemotherapy at our hospital.
  • Following systematic chemotherapy, 23 local injections of cytotoxic T lymphocytes were performed.
  • Immunotherapy using cytotoxic T lymphocytes may be a useful strategy for controlling recurrent malignant melanoma.
  • [MeSH-major] Immunotherapy / methods. Melanoma / therapy. Nasal Cavity. Nose Neoplasms / therapy. T-Lymphocytes, Cytotoxic / transplantation
  • [MeSH-minor] Female. Humans. Interleukins / therapeutic use. Mediastinal Neoplasms / secondary. Mediastinal Neoplasms / therapy. Middle Aged. Neoplasm Recurrence, Local. Transplantation, Autologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17165592.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Interleukins
  •  go-up   go-down


62. Doval DC, Bhatia K, Pavithran K, Sharma JB, Vaid AK, Hazarika D: Breast carcinoma with metastasis to the gallbladder: an unusual case report with a short review of literature. Hepatobiliary Pancreat Dis Int; 2006 May;5(2):305-7
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gallbladder metastases are very rare and usually arise from malignant melanoma, renal cell carcinoma and cervical carcinoma.
  • We hereby report a 54-year-old lady who was diagnosed as having breast carcinoma and underwent modified radical mastectomy.
  • One month after the operation, she developed acute abdominal pain and underwent cholecystectomy after clinical investigation.
  • Being considered a patient with metastatic breast carcinoma she was subjected to taxane and anthracycline-based palliative chemotherapy.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16698597.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 15
  •  go-up   go-down


63. Weisz B, Schiff E, Lishner M: Cancer in pregnancy: maternal and fetal implications. Hum Reprod Update; 2001 Jul-Aug;7(4):384-93
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer in pregnancy: maternal and fetal implications.
  • Cancer is the second leading cause of death in women during their reproductive years, and complicates approximately 0.1% of all pregnancies.
  • When cancer occurs during gestation it poses immense pressure on the pregnant patient, her relatives and her physicians.
  • As cancer is diagnosed during gestation, it raises conflicts between optimal maternal therapy and fetal well-being.
  • In this review, the available data are analysed regarding the impact of pregnancy on the course of the disease, and the effects of the malignant process and its treatment on both the mother and her fetus.
  • Here, attention is focused on the most common malignancies associated with pregnancy; cervical and breast cancer, malignant melanoma and lymphoma.
  • In addition, attention is focused on the available data regarding the impact of cytotoxic and radiation treatments on the mother and fetus.
  • [MeSH-minor] Adult. Breast Neoplasms / pathology. Breast Neoplasms / physiopathology. Breast Neoplasms / therapy. Drug-Related Side Effects and Adverse Reactions. Embryonic and Fetal Development / drug effects. Female. Humans. Infant, Newborn. Lymphoma / pathology. Lymphoma / therapy. Melanoma / pathology. Melanoma / physiopathology. Melanoma / therapy. Pregnancy. Radiotherapy / adverse effects. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / physiopathology. Uterine Cervical Neoplasms / therapy

  • Genetic Alliance. consumer health - Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11476351.001).
  • [ISSN] 1355-4786
  • [Journal-full-title] Human reproduction update
  • [ISO-abbreviation] Hum. Reprod. Update
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 140
  •  go-up   go-down


64. Pedersen MØ, Larsen A, Stoltenberg M, Penkowa M: The role of metallothionein in oncogenesis and cancer prognosis. Prog Histochem Cytochem; 2009;44(1):29-64
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of metallothionein in oncogenesis and cancer prognosis.
  • The antiapoptotic, antioxidant, proliferative, and angiogenic effects of metallothionein (MT)-I+II has resulted in increased focus on their role in oncogenesis, tumor progression, therapy response, and patient prognosis.
  • Studies have reported increased expression of MT-I+II mRNA and protein in various human cancers; such as breast, kidney, lung, nasopharynx, ovary, prostate, salivary gland, testes, urinary bladder, cervical, endometrial, skin carcinoma, melanoma, acute lymphoblastic leukemia (ALL), and pancreatic cancers, where MT-I+II expression is sometimes correlated to higher tumor grade/stage, chemotherapy/radiation resistance, and poor prognosis.
  • However, MT-I+II are downregulated in other types of tumors (e.g. hepatocellular, gastric, colorectal, central nervous system (CNS), and thyroid cancers) where MT-I+II is either inversely correlated or unrelated to mortality.
  • Large discrepancies exist between different tumor types, and no distinct and reliable association exists between MT-I+II expression in tumor tissues and prognosis and therapy resistance.
  • This review aims at discussing the role of MT-I+II both as a prognostic marker for survival and therapy response, as well as for the hypothesized role of MT-I+II as causal oncogenes.
  • [MeSH-major] Biomarkers, Tumor. Metallothionein / physiology. Neoplasms / diagnosis. Neoplasms / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19348910.001).
  • [ISSN] 0079-6336
  • [Journal-full-title] Progress in histochemistry and cytochemistry
  • [ISO-abbreviation] Prog Histochem Cytochem
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 9038-94-2 / Metallothionein
  • [Number-of-references] 203
  •  go-up   go-down


65. Savoia P, Fierro MT, Zaccagna A, Bernengo MG: Metastatic melanoma of the heart. J Surg Oncol; 2000 Nov;75(3):203-7
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic melanoma of the heart.
  • BACKGROUND: Malignant melanoma has an unpredictable biologic behavior and is the neoplasm with the greatest propensity for cardiac involvement.
  • METHODS: We reviewed 2,810 patients with histologically confirmed malignant melanoma, who were diagnosed and followed up by our clinic.
  • RESULTS: Five cases of metastatic melanoma of the heart were identified out of 314 melanoma patients with visceral involvement.
  • One case of a 53-year-old woman, who died unexpectedly during her first chemotherapy course, is described in detail.
  • Postmortem examination determined the cause of death to be the presence of multiple melanoma metastases in the heart, even though the patient had shown no signs of cardiac involvement.
  • CONCLUSIONS: The unpredictable biologic behavior of melanoma may lead to unusual metastatic sites, and, therefore, the heart also should be included in routine examinations.
  • [MeSH-major] Heart Neoplasms / pathology. Heart Neoplasms / secondary. Melanoma / pathology. Melanoma / secondary
  • [MeSH-minor] Adult. Female. Head and Neck Neoplasms / pathology. Humans. Male. Middle Aged. Thoracic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 11088053.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


66. Gerger A, Smolle-Jüttner FM, Samonigg H, Wehrschütz M, Smolle J: Asymptomatic primary malignant melanoma of the esophagus. Onkologie; 2007 Apr;30(4):206-8
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asymptomatic primary malignant melanoma of the esophagus.
  • BACKGROUND: Primary malignant melanoma of the esophagus is an exceedingly rare disease.
  • This tumor is typically aggressive and disseminates early via the lymphatics and the bloodstream with a mean survival time between 10 and 15 months after radical surgical resection.
  • The role of chemotherapy and immunotherapy is unclear.
  • No treatment plan for the disease has yet been established.
  • CASE REPORT: A 78-year-old man came for a checkup with a medical history of reflux esophagitis and chronic gastritis.
  • Esophagogastroscopy showed a bluishgray tumor of the esophagus, and histology revealed features consistent with malignant melanoma.
  • The patient underwent total transhiatal esophagectomy with curative intention, and esophagogastric anastomosis was performed.
  • Immunohistochemistry revealed tumor cells strongly positive for the melanoma-specific antigen HMB45 and protein S-100, and negative for cytokeratin.
  • A proposed postoperative chemotherapy was declined by the patient.
  • Nine months after surgery, the patient's condition deteriorated, and a mediastinal lymph node conglomerate was found.
  • Two months later, he died of bleeding into the cervical soft tissue.
  • CONCLUSION: Up to date, radical surgical resection is the main treatment.
  • Very little is known about the benefits of chemotherapy and immunotherapy.
  • However, these therapeutic modalities may play an important role in the future.
  • [MeSH-major] Esophageal Neoplasms / diagnosis. Melanoma / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Disease-Free Survival. Esophagectomy. Esophagitis, Peptic / etiology. Esophagoscopy. Gastritis / etiology. Humans. Lymphatic Metastasis. Male. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17396044.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


67. Saha VP, Srivastava A, Saha S, Ghosh A, Chakraborty D: Cutaneous matastasis from sino-nasal malignant melanoma - a rare case report. Indian J Otolaryngol Head Neck Surg; 2008 Dec;60(4):369-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous matastasis from sino-nasal malignant melanoma - a rare case report.
  • To report a case of disseminated cutaneous metastasis from malignant melanoma of sino-nasal region.
  • Malignant melanoma of sino-nasal region was diagnosed and chemotherapy was started.
  • The patient developed cutaneous deposits after two cycles of chemotherapy.
  • The patient developed cutaneous deposits during the course of chemotherapy.
  • Excision biopsy from cutaneous deposits revealed malignant melanoma.
  • A rare case of diffuse cutaneous metastasis of malignant melanoma is presented here along with review of literature.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1971 Jul;100(1):141-3 [5147022.001]
  • [Cites] Int J Oral Maxillofac Surg. 1995 Jun;24(3):229-32 [7594758.001]
  • [Cites] J Laryngol Otol. 1994 Oct;108(10):896-7 [7989845.001]
  • [Cites] Otolaryngol Head Neck Surg. 2001 Mar;124(3):248-52 [11240984.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1993 Mar;119(3):326-30 [8435173.001]
  • [Cites] Head Neck Surg. 1980 Jul-Aug;2(6):497-508 [6248488.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1995 Nov;121(11):1246-8 [7576469.001]
  • [Cites] Cutis. 1987 Feb;39(2):119-21 [3829718.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Sep;11(9):1709-12 [3928547.001]
  • (PMID = 23120584.001).
  • [ISSN] 2231-3796
  • [Journal-full-title] Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
  • [ISO-abbreviation] Indian J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3476808
  • [Keywords] NOTNLM ; Chemotherapy / Cutaneous metastasis / Malignant melanoma
  •  go-up   go-down


68. Lee CH, Moon KY, Chung CK, Kim HJ, Chang KH, Park SH, Jahng TA: Primary intradural extramedullary melanoma of the cervical spinal cord: case report. Spine (Phila Pa 1976); 2010 Apr 15;35(8):E303-7
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary intradural extramedullary melanoma of the cervical spinal cord: case report.
  • STUDY DESIGN: Case report.
  • OBJECTIVE: We report a case of primary intradural extramedullary melanoma of the cervical spinal cord in a nonwhite patient.
  • SUMMARY OF BACKGROUND DATA: Melanoma occurs most commonly in white populations and is rare in Asian populations.
  • Primary malignant melanoma of the spinal cord is a rare disease entity that predominately affects the middle or lower thoracic spine.
  • Preoperative magnetic resonance imaging (MRI) of the cervical spine suggested a multiloculated subdural hematoma in the subacute stage that spread from the level of C1 to the level of C6.
  • RESULTS: A standard posterior midline approach was used under the impression that the subacute subdural hematoma was caused by a hidden vascular anomaly or a rare, intradural, pigmented tumor.
  • Histopathological investigation confirmed malignant melanoma.
  • No hypermetabolic lesions were noted on whole-body FDG-PET.
  • Additional dermatologic and ophthalmologic examinations did not reveal any other foci of primary melanoma.
  • The patient was discharged with improvement of motor weakness.
  • Subsequent radiotherapy and chemotherapy were administered.
  • CONCLUSION: Unlike most cases of primary intradural melanoma, this patient presented with unusual radiologic findings in the cervical spinal cord.
  • The case described in the present study illustrates that primary spinal cord melanoma is rare and must be diagnosed with caution due to its variable clinical and radiologic presentation.
  • [MeSH-major] Melanoma / pathology. Melanoma / therapy. Spinal Cord Compression / etiology. Spinal Cord Neoplasms / pathology. Spinal Cord Neoplasms / therapy
  • [MeSH-minor] Activities of Daily Living. Adult. Asian Continental Ancestry Group. Biomarkers, Tumor. Combined Modality Therapy. Decompression, Surgical. Diagnosis, Differential. Drug Therapy. Humans. Laminectomy. Magnetic Resonance Imaging. Male. Muscle Weakness / etiology. Neurosurgical Procedures. Paresthesia / etiology. Positron-Emission Tomography. Radiotherapy. Spinal Cord / pathology. Spinal Cord / physiopathology. Spinal Cord / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20308942.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


69. Anatolian Medical Oncology Society Group, Ustaalioglu BB, Gumus M, Unal A, Cayir K, Sever O, Bilici A, Elkiran ET, Karaca H, Benekli M, Karaoglu A, Seker M: Malignancies diagnosed during pregnancy and treated with chemotherapy or other modalities (review of 27 cases): multicenter experiences. Int J Gynecol Cancer; 2010 Jul;20(5):698-703
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignancies diagnosed during pregnancy and treated with chemotherapy or other modalities (review of 27 cases): multicenter experiences.
  • BACKGROUND: Cancer is the second leading cause of death in women of reproductive age.
  • The most common tumors diagnosed during pregnancy are breast and cervix cancer, Hodgkin lymphoma and non-Hodgkin lymphoma, leukemias, and malignant melanoma.
  • The aim of therapy in pregnancy is to give optimal treatment to the mother without harm to the fetus.
  • In the first trimester, organogenesis continues, so chemotherapy should not be given because of increasing risk of spontaneous abortion, fetal malformation, and mortality.
  • We evaluated mostly seen tumors during pregnancy and assessed treatment type and outcome of pregnancy after chemotherapy in our population.
  • RESULTS: The tumors associated with pregnancy were breast cancer, hematologic malignancies,gynecologic malignancies, sarcomas, and others.
  • The chemotherapy regimens were given in 17 of 27 patients in the second or third trimester of pregnancy.
  • Four of the patients were diagnosed with cervical cancer, hemangiopericytoma, chronic myeloid leukemia,and breast cancer during the first trimester, so their pregnancies were ended by therapeutic abortion.
  • Although 1 of the 3 fetuses who were exposed to chemotherapy in utero at the second or third trimester was born prematurely and low birth weight was diagnosed in the other 2 fetuses, fetal malformation was not seen in any of them.
  • CONCLUSIONS: We reported herein 27 patients with malignancies diagnosed during pregnancy; 17 patients received chemotherapy during the gestational period without any fetal or maternal abnormalities.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Pregnancy Complications, Neoplastic / drug therapy. Prenatal Exposure Delayed Effects / chemically induced

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20973261.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


70. Fink W, Zimpfer A, Ugurel S: Mucosal metastases in malignant melanoma. Onkologie; 2003 Jun;26(3):249-51
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucosal metastases in malignant melanoma.
  • BACKGROUND: We present the case of a patient with malignant melanoma stage IV according to the American Joint Committee on Cancer (AJCC) classification and an unusual pattern of metastasis to the mucosa of the esophagus, the stomach, the bladder and the palatine tonsil.
  • CASE REPORT: A 38-year-old male patient with metastatic malignant melanoma of stage III (AJCC) was admitted for initiation of adjuvant therapy.
  • 4 months earlier a primary melanoma of the left upper leg had been excised and 2 months later the patient had undergone a left inguinal lymph node dissection revealing 2 metastatic lymph nodes.
  • On admission the patient complained of a sore throat and right cervical lymphadenopathy.
  • He underwent a tonsillectomy and a lymphadenectomy which both revealed melanoma metastases.
  • Two cycles of dacarbazine (DTIC) chemotherapy were performed during which the patient developed cutaneous metastases, dyspepsia, and mild hematemesis.
  • A few weeks later the patient developed macroscopic hematuria.
  • The patient is currently alive with progressive disease.
  • RESULTS: This case presents common and uncommon sites of metastatic melanoma to the mucosa with the typical clinical manifestations in a single patient.
  • [MeSH-major] Esophageal Neoplasms / secondary. Melanoma / secondary. Skin Neoplasms / pathology. Stomach Neoplasms / secondary. Tonsillar Neoplasms / secondary. Urinary Bladder Neoplasms / secondary
  • [MeSH-minor] Adult. Combined Modality Therapy. Diagnosis, Differential. Gastric Mucosa / pathology. Humans. Male. Mucous Membrane / pathology. Neoplasm Staging. Tomography, Emission-Computed






Advertisement